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Isoflavonoids or pharmaceutically acceptable salts thereof or 
pharmaceutically acceptable compositions thereof for the 
treatment of prostate cancer or for the treatment or inhibition 
of prostate cancer metastasis in a patient in need thereof are 
disclosed. 
13 Claims, No Drawings 
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TREATMENT OF CANCER 














This application claims the benefit of U.S. Provisional 
Application No. 62/159,669 filed May 11, 2015 the entire 10 
disclosure of which is hereby incorporated by reference 
wherein Ar is an aryl or heteroaryl; n is an integer from 1 to 
5; each Xis independently a halide, or alkoxy, or more than 
one X on Ar together form a cyclic ether structure; and 
wherein the compound is substituted on the C-2 position 
herein. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH 
This invention was made with govermnent support under 
Contract No. 2P20 RR020171 awarded by The National 
Institutes of Health. The Government has certain rights in 
the invention. 
TECHNICAL FIELD 
The present disclosure is directed to compounds having 
antineoplastic activity. In particular, the disclosure is 
directed to 3-aryl-substituted 4H-chromen-4-ones, com­
monly referred to as isoflavonoids, and use of such com­
pounds to inhibit cancer cell growth, e.g., prostate cancer, a 
patient in need thereof. 
BACKGROUND 
Prostate cancer represents a significant health care burden 
and is the second leading cause of cancer-related mortality 
in men. See Siegel, R.; Ma, J.; Zou, Z.; Jemal, A. CA Cancer
15 
with H, alkyl, cycloalkyl or alkoxy, substituted on the C-5, 
C-6, C-7, and C-8 positions independently with H, hydroxy
(OH), alkyl, cycloalkyl, alkoxy, or the substituents on either
C-6 and C-7 or C-7 and C-8 together form a substituted or
unsubstituted, saturated or unsaturated, cyclic or polycyclic
20 ring structure which includes at least one chalcogen, e.g., 
oxygen or sulfur. The alkyl, cycloalkyl, alkoxy and ring 
structures can be unsubstituted or substituted. Such substitu­
ents include one or more of an amine (NR2R3), hydroxy,
25 
ester, e.g., an acetoxy, alkoxy, carbonyl. 
Embodiments include one or more of the following fea­
tures individually or combined. For example, embodiments 
of the present disclosure include 3-aryl-4H-chromen-4-ones 
in which Ar is heteroaryl, such as pyridinyl, diazinyl, 
pyrimidinyl, oxazolyl or imidazolyl. In some embodiments, 
30 Ar is aryl, e.g., phenyl. In other embodiments, the 3-aryl-
4H-chromen-4-one has formula (II): 
(II) 
35 
J. Clin. 2014, 64, 9. Among the challenges in this area is the 40 
problem of recurrent prostate cancer following androgen­
deprivation therapy (i.e., castration). Medical castration ini­
tially depletes androgens such as testosterone and its 
reduced form, 5a-dihydrotestosterone. However, the cancer 
inevitably reoccurs, and a previously unappreciated but 45 
sinister backdoor pathway (Fiandalo, M. V.; Wilton, J.; 
Mohler, J. L. Int. J. Biol. Sci. 2014, 10, 596) converts an 
intermediate in cholesterol metabolism, 17a-hydroproges­
terone first to 4-androstene-3,17-dione and then to dihy­
drotestosterone without passing through testosterone. 50 
Accordingly, there is a continuing need to develop therapies 
In various embodiments, the substituents on the 3-aryl-
4H-chromen-4-ones (II) include those wherein the C-2 sub­
stituent is hydrogen H or methyl; Ar includes one or two X 
groups on the aryl that can be halogens ( e.g., fluorine or 
chlorine) or alkoxy groups (e.g., methoxy) or together form 
a ring structure (e.g., methy lenedioxy or dimethy lenedioxy); 
the C-5 substituent is hydrogen H, hydroxy (OH) or alkoxy 
(OR1 ) where R1 is an alkyl or cycloalkyl group; the C-6
substitutent is hydrogen H; the C-7 substituent is hydroxy or 
alkoxy (OR 1 ) where R 1 is an alkyl or cycloalkyl group; C-8
is hydrogen H, methyl, alkyl or substituted alkyl, such as 
alkyl-Y where Y represents (NR2R3), hydroxy, ester, e.g., an 
to reduce the elevated levels of these androgens as a means 
to treat recurrent prostate cancer. 
SUMMARY OF THE DISCLOSURE 
Advantages of the present disclosure include 3-aryl-sub­
stituted 4H-chromen-4-ones or pharmaceutically acceptable 
salts thereof or pharmaceutically acceptable compositions 
thereof for the treatment of prostate cancer or for the 
treatment or inhibition of recurrent prostate cancer in a 
patient in need thereof. 
55 acetoxy, alkoxy, where R2 and R3 are independently H,
alkyl, e.g., a C1 _8 alkyl, or C-6 and C-7 together form a ring 
structure including an oxygen, or C-7 and C-8 together form 
a ring structure including an oxygen. 
Another aspect of the present disclosure includes a phar-
60 maceutical composition of any one or more of the 3-aryl-
4H-chromen-4-ones of the present disclosure or one or more 
pharmaceutically acceptable salts thereof, e.g., one or more 
compounds of formula (I) and/or formula (II) and/or one or 
These and other advantages are satisfied, at least in part, 65 
by a 3-aryl-4H-chromen-4-one compound having formula 
more pharmaceutically acceptable salts of compounds 
according to formulas (I) and/or (II), in combination with a 
pharmaceutically acceptable additive, e.g., a pharmaceuti-
(I) or pharmaceutically acceptable salt thereof: cally acceptable carrier or excipient. In one aspect of the 
US 9,718,799 B2 
3 
present disclosure, the pharmaceutical compositions com­
prise an effective amount of at least one 3-aryl-4H-chromen-
4-one or its pharmaceutically acceptable salt.
Another aspect of the present disclosure includes a
method of treating prostate cancer. The method comprising 5 
administration to a patient in need of such treatment an 
effective amount of one or more of the 3-aryl-4H-chromen-
4-ones of the present disclosure or pharmaceutically accept­
able salt thereof or a pharmaceutical composition thereof. 
Additional advantages of the present invention will 
10 
become readily apparent to those skilled in this art from the 
following detailed description, wherein only the preferred 
embodiment of the invention is shown and described, simply 
by way of illustration of the best mode contemplated of 
15 
carrying out the invention. As will be realized, the invention 
is capable of other and different embodiments, and its 
several details are capable of modifications in various obvi-
ous respects, all without departing from the invention. 20 
DETAILED DESCRIPTION OF THE 
DISCLOSURE 
The present disclosure relates to 3-aryl-4H-chromen-4- 25 
ones that can be used in the treatment of prostate cancer. 
Considerable lore surrounds the health benefits associated 
4 
We found that removal of some hydroxyl groups from 
these natural products and replacement of these groups with 
functional groups capable of hydrogen bonding and van der 
Waals interactions led to new agents with unique biological 
targets. 
An advantage of the present disclosure includes 3-aryl-
4H-chromen-4-ones or pharmaceutically acceptable salts 
thereof that can be used for the treatment of prostate cancer 
or for the treatment or inhibition of recurrent prostate cancer 
in a patient in need thereof. The 3-aryl-4H-chromen-4-ones 
of the present disclosure include compounds of formula (I) 











with the consumption of foods rich in natural products in the wherein Ar represents aryl, e.g., phenyl, or heteroaryl, e.g., 
isoflavone family. In particular, soy products containing 30 
pyridinyl, diazinyl, pyrimidinyl, oxazolyl or imidazolyl. The 
7-hydroxyisoflavones, such as daidzein (A) and genistein
(B), captured attention for alleged benefits with respect to
variable n represents the number ofX groups on Ar and can 
be an integer from 1 to 5. Each X, e.g., X1 , X2, X3 , X4, 
cancer prevention and treatment of prostate cancer. See (a)
35 and/or X
5, is independently a halide, e.g., a fluoro, chloro, or 
Munro, I. C.; Harwood, M.; Hlywka, J. J.; Stephen, A. M.;
bromo, or alkoxy (---OR 1 where R1 is an alkyl or 
cycloalkyl), or more than one X on Ar together form a cyclic 
ether structure, e.g., X1 and X2 on Ar together form a 
Doull, J.; Flamm, W. G.;Adlercreutz, H. Nutr. Rev. 2003, 61,
1; (b) Adlercreutz, H. Scand. J. Clin. Lab. Invest. 1990, 50,
3; (c) Andres, S.; Abraham, K.; Appel, K. E.; Lampen, A.
Crit. Rev. Toxicol. 2011, 41, 463. Unfortunately, naturally
40 ---0-R- or -O-R---0- ring, where R is a  di-radical 
occurring isoflavones and their metabolites possess numer- organo group. Examples of such groups include a methyl-
ous biological activities, including effects on androgen enedioxy, dimethylenedioxy, etc. The 3-aryl-4H-chromen-
receptor expression and enzymes associated with androgen 
45 
4-one is substituted at each of its C-2, C-5, C-6, C-7, C-8
metabolism. Hamilton-Reeves, J. M.; Rebello, s. A.; positions. Each of substituent on these positions can be the 








alkyl or cycloalkyl; e.g., methyl, ethyl, cyclopropyl; alkoxy; 
50 
----COR 1 , e.g., acetyl (----COCH3); ester, etc. In addition, the 
substituents on either C-6 and C-7 or the substituents on C-7 
and C-8 together can form a substituted or unsubstituted, 
saturated or unsaturated, cyclic or polycyclic ring structure 
55 which includes at least one chalcogen, e.g., oxygen or sulfur. 
60 
65 
In an embodiment of the present disclosure, the compound 
is substituted on the C-2 position with H, alkyl, or 
cycloalkyl, substituted on the C-5, C-6, C-7, and C-8 posi-
tions independently with H, hydroxy (OH), alkyl or 
cycloalkyl, alkoxy (---OR 1 where R1 is an alkyl or 
cycloalkyl), or the substituents on C-6 and C-7 or the 
substituents on C-7 and C-8 together form a substituted or 
unsubstituted, saturated or unsaturated, cyclic or polycyclic 
ring structure which includes at least one chalcogen. 
US 9,718,799 B2 
5 
The alkyl, cycloalkyl, alkoxy and ring structures 
described for the various groups and substituents can be 
unsubstituted or substituted. For example, alkyl, cycloalkyl, 
alkoxy and ring structures can be substituted with an amine 
(NR2R3), hydroxy, ester, e.g., an acetoxy, alkoxy, carbonyl, 5 
where R2 and R3 represent independently H, alkyl, e.g., a 
C
1
_8 alkyl. In some embodiments, C-7 and C-8 indepen­
dently can be CH
2
0Y1 where Y1 is hydrogen, alkyl, e.g., 
methyl, acetyl, etc. 
In an embodiment of the present disclosure, the 3-aryl-
10 
4H-chromen-4-one is a compound of formula (II) or a 




where C-2, C-5, C-6, C-7, C-8, X and n are as defined above 
25 
including all embodiments thereof. 
The compounds of the present disclosure, including com-
pounds of Formula (I) and Formula (II), can be prepared by 
methods disclosed herein or any other method known in the 
30 
art. For example, the regioselective application of the Betti 
reaction (also called the Marmich reaction) to phenols and 
�-naphthols provides access to an array of substituted aro­
matic systems and was adapted in this disclosure for the 
35 
preparation of substituted 3-aryl-4H-chromen-4-ones. See 
(a) M. Betti, Gazz. Chim. Ital., 1900, 30, 301-309; (b) M.
6 
well as cyclic counterparts in which there is a substituted or 
unsubstituted, saturated or unsaturated, cyclic or polycyclic 
ring structure which includes at least one chalcogen, e.g., 
oxygen or sulfur, between C-6 and C-7 or between C-7 and 
C-8 (Scheme 1 ).
Scheme 1. Biologically active 3-aryl-4H-chromen-4 ones 1 and 2. 
2 
HO 
Betti, Gazz. Chim. Ital., 1900, 30, 310-316; ( c) M. Betti, A literature report of antineoplastic activity within related 
Gazz. Chim. Ital., 1906, 36, 392-394; (d) L. 0. Paquette, Ed., 40 natural products included chromones such as 8-(methoxym-
Encyclopedia of Reagents for Organic Synthesis, 1995, ethyl)eugenin that showed moderate cytotoxicity against 
Wiley, UK, 4, 2582. Natural isoflavones, such as genistein P388 leukemia cells. See Y. Feng, J. W. Blunt, A. L. J. Cole 
(B) from soybeans, were used in clinical trials for prostate and M. H. G. Munro, J. Nat. Prod. 2002, 65, 1681-1682. 
cancer prevention and treatment. See Perabo, et al., Prostate 
Cancer and Prostate Diseases, 2008, 11, 6-12. 
In the course of developing synthetic 3-aryl-4H-chromen-
4-ones as antineoplastic agents, we explored the application 
45 Reports, such as this, are limited because 8-(hydroxymethyl) 
isoflavonoids are not readily found in nature. As a conse­
quence, this disclosure reveals a general synthetic route to 
these variously substituted analogs as well as biologically 
of the Betti reaction to isoflavonoids. The rationale for 50 active compounds useful for the treatment of prostate cancer. 
developing these new 3-aryl-4H-chromen-4-ones derives Application of the Betti reaction to hydroxylated 3-aryl-
from the low efficacy of naturally occurring isoflavones as 
antineoplastic agents and the non-specific biological effects 
4 H-chromen-4-ones using bis(N,N-dimethy !amino )methane 
in 1,4-dioxane at 70° C. provided access to dimethylamin-
of the naturally occurring isoflavones and their metabolites. 55 omethyl-substituted systems, and their subsequent manipu­
The IC
50 
of naturally occurring genistein (B) in different lation furnished the desired acetoxymethyl, hydroxymethyl, 
cancer cell lines was only ca. 15-100 µM, and the specific and alkoxymethyl derivatives for biological evaluation. See, 
biological targets of naturally occurring isoflavones as anti- e.g., Tramontini et al., Mannich Bases-Chemistry and Uses, 
60 
neoplastic agents was unclear. In this disclosure, a prolif- 1994, CRC Press, Boca Raton, Fla. Synthesis of appropriate 
eration assay using a prostate cancer PC3 cell line provided 
a reasonable surrogate to interrogate structure-activity 
(SAR) relationships within C-2 substituted and either C-6 or 
C-8 acetoxymethyl-, hydroxymethyl-, and alkoxymethyl­
substituted 3-aryl-7-hydroxy-4H-chromen-4-ones 1 and 2 as 
65 
starting materials involved the regioselective methylation of 
the C-7 hydroxy group in 5,7-dihydroxyisoflavonoids to 
afford 5-hydroxy-2',7-dimethoxyisoflavone (3a) and 4',7-
dimethoxygenistein (3b) (Scheme 2) using dimethyl sulfate 
in the presence of potassium carbonate. 
US 9,718,799 B2 
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a C-2 =H, Ar' = CoR,-2-0CH3, C-7 =OCH3, C-5 =OH 
b C-2 = H, Ar' = CoR,-4-0CH3, C-7 = OCH3, C-5 = OH 
c C-2 =H, Ar' = CoR,-2-0CH3, C-7 =OH, C-5 =H 
d C-2 =H,Ar' = CoR,-4-0CH3, C-7 =OH, C-5 =H
e C-2 =CH3, Ar' = C,IL,-4-0CH3, C-7 =OH, C-5 =H
Legend: a, CH2(N(CH3),),, DMF, reflux. 
0 
In contrast to 5,7-dihydroxy-substituted 3-aryl-4H-
30 
chromen-4-ones, which undergo bis-aminomethylation, the 
5-hydroxy-substituted 3-aryl-4H-chromen-4-ones 3a and 3b
underwent mono-aminomethylation with bis(N,N-dimethyl­
amino )methane in 1,4-dioxane to give a mixture of the 6-
35 
and S-(N,N-dimethylaminomethyl) derivatives 4a-4b and 
5a-5b, respectively, (Scheme 2) in which the C-6 isomer 
predominated. The structures of these isomers were estab­
lished by HMBC NMR spectroscopy. The 6-(N,N-dimeth- 40 
ylamino )methyl derivatives 4a and 4b have cross-peaks for 
H-2 with C-Sa and for H-S with C-Sa. Similar cross-peaks
were observed for H-2 with C-Sa and for the methylene 
protons at C-S with C-Sa in compounds Sa and 5b. The 45 
aminomethylation of the C-7 hydroxylated 3-aryl-4H-
4 
0 
Scheme 3. Conversion of Betti bases 4 and 5 to acetoxymethyl 







chromen-4-ones 3c-3e with bis(N,N-dimethylamino )meth- a c-2 =H, Ar' = coIL,-2-oCH,, c-7 = ocH3, c-s = OH 
ane in isopropanol or 1,4-dioxane gave only the S-N,N- b c-2 =H,Ar' = CoR,-4-0CH,, C-7 =OCH,, c-s = OH 
50 cC-2=H,Ar' = ColL,-2-0CH 3, C-7=0H,C-5=H 
dimethylamino derivatives 5c-5e. In summary, 
d C-2 = H, Ar' = CoR,-4-0CH3, C-7 = OH, C-5 = H
5-hydroxylated and 7-hydroxylated 3-aryl-4H-chromen-4- e c-2 =CH3, Ar' = CoR,-4-0CH3, C-7 =OH, c-s =H
ones underwent the desired aminomethylations using bis(N, 
N-dimethylamino )methane and exhibited regioselectivity in 55 
the C-5 hydroxylated cases in favor of the C-6 (dimethyl-
Legend: a, Ac20, KOAc. 
Hydrolysis of the diacetates 6a-6b or 7a-7e using a 2:1 
ratio of0.2M aqueous sulfuric acid in 1,4-dioxane furnished 
the corresponding hydroxymethyl 3-aryl-4H-chromen-4-
ones Sa-Sb or 9a-9e, respectively (Scheme 4). Hydrolysis of 
amino )methyl derivatives 4 and regiospecificity in the C-7 
hydroxylated cases in favor of the desired C-S (dimethyl­
amino )methyl derivatives 5. 
Direct conversion of the Betti bases 4 and 5 to the 
corresponding C-6 or C-S acetoxymethyl derivatives 
involved heating the Betti bases 4a-4b or 5a-5e with acetic 
anhydride in presence of potassium acetate to afford the 
corresponding diacetates 6 and 7 in excellent yield (Scheme 
3). 
60 the diacetates 6 or 7 using hydrochloric acid in methanol led 
directly to the C-6 or C-S-methoxymethyl 3-aryl-4H­
chromen-4-ones 10 and 11, respectively. The substitution of 
ethanol or isopropanol for methanol led, as expected, to 
other alkoxymethyl-substituted analogs. Treatment of S-hy-
65 droxymethyl 3-aryl-4H-chromen-4-ones with hydrochloric 
acid in methanol furnished to the S-methoxymethyl analogs 
and treatment of S-acetoxymethyl derivatives with sodium 
US 9,718,799 B2 
9 
hydroxide in methanol also led to the 8-methoxymethyl 
3-aryl-4H-chromen-4-ones (Scheme 4).
10 
structure in that it retained potency even at 1 mM concen­
tration. 
Scheme 4. Conversion of acetoxymethyl derivatives 6 and 7 to 
















a C-2 =H, Ar'= CoR,-2-0CH3, C-7 =OCH3, C-5 =OH 
b C-2 = H, Ar'= CoR,-4-0CH3, C-7 = OCH3, C-5 = OH 
c C-2 =H, Ar'= ColL,-2-0CH3, C-7 =OH, C-5 =H 
d C-2 =H,Ar' = CoR,-4-0CH3, C-7 =OH, C-5 =H 
e C-2 =CH3, Ar'= C6IL,-4-0CH3, C-7 =OH, C-5 =H 
Legend: a, 0.2M H2S04, aq. 1,4-dioxane; b, HCI, MeOH; c, NaOH, MeOH. 
A screening program using an in vitro PC3 prostate cancer 
cell line revealed that several 7-hydroxylated 3-aryl-4H­
chromen-4-ones 2 with C-8 acetoxymethyl, hydroxymethyl 
40 
or alkoxymethyl substituents exhibited antineoplastic activ-
ity in the 1-10 µM range (Table 1). In general, we observed 
that C-8 substituted analogs 7, 9 and 11 were more potent at 
10 µM concentrations than the C-6 substituted analogs 6, 8 
and 10, respectively. Within the C-8 series, the acetoxym-
45 
ethyl- and hydroxymethyl-3-aryl-4H-chromen-4-ones were 
more potent than the corresponding alkoxymethyl-substi­
tuted 3-aryl-4H-chromen-4-ones. Also within the C-8 series, 
the 3-aryl-4H-chromen-4-ones that possessed a 4-methoxy- 50 
phenyl group were in general preferable to those with a 
2-methoxyphenyl group. For example, 3-aryl-4H-chromen-
4-ones 7d and 7e were more potent than 7c; 3-aryl-4H­
chromen-4-ones 9b, 9d and 9e were more potent than 9c; 55
and 3-aryl-4H-chromen-4-ones lib was more potent than
lie. Other substituents than methoxy groups on the 3-phenyl
group were also explored and those with halogens were also
biologically active. Finally, within the C-8 series, those 60 




Percent inhibition of proliferation in a prostate 
cancer PC3 cell assay by isoflavonoids. 
Inhibition 
Isoflavonoid C-6 or C-8 Substituent at 10 µM (%) 
6a 6-acetoxymethyl 17.1 ± 5.9 
6b 6-acetoxymethyl 51.7 ± 5.7 
7b 8-acetoxymethyl 20.2 ± 2 
7c 8-acetoxymethyl 20.6 ± 3.8 
7d 8-acetoxymethyl 99.2 ± 0.4 
7e 8-acetoxymethyl 98.2 ± 1.5 
Sa 6-hydroxymethyl 14.6 ± 3.2 
Sb 6-hydroxymethyl 0 ± 16 
9b 8-hydroxymethyl 79.5 ± 3.6 
9c 8-hydroxymethyl 0 ± 16 
9d 8-hydroxymethyl 99.5 ± 0.2 
9e 8-hydroxymethyl 99.5 ± 0.5 
lOa 6-methoxymethyl 53.4 ± 8 
!Ob 6-methoxymethyl 0 ± 27 
lla 8-methoxymethyl 0 ± 1.3 
llb 8-methoxymethyl 96.8 ± 0.8 
llc 8-methoxymethyl 0 ± 7.4 
lld 8-methoxymethyl 34.9 ± 3.3 
In summary, the Betti reaction ofC-5 or C-7 hydroxylated 
3-ary 1-4 H-chromen-4-ones provided N,N-( dimethy !amino)
methyl derivatives that were readily converted to acetoxym­
ethyl, hydroxymethyl, or alkoxymethyl-substituted 3-aryl-
4H-chromen-4-ones. In particular, the 5-hydroxylated
well as either 8-acetoxymethyl or 8-hydroxymethyl groups
(e.g., 7d and 7e, 9d and 9e) were in general more potent than
3-ary 1-4 H-chromen-4-ones with 5-hydroxy-7 -methoxy
groups (e.g., 7b and 9b). The 3-aryl-4H-chromen-4-one 7d
with a C-8 acetoxymethyl emerged as a promising lead
65 3-aryl-4H-chromen-4-ones 3a-3b afforded C-6 Betti bases 
4a-4b regioselectively that led via the diacetates 6a-6b to the 
C-6 alkoxymethyl derivatives 1 Oa-lOb. Analogous reactions
US 9,718,799 B2 
11 
of the 7-hydroxylated 3-aryl-4H-chromen-4-ones 3c-3e 
afforded the C-8 Betti bases 5c-5e regiospecifically, and the 
diacetates 7 c-7 e derived from these Mannich bases under­
went substitutions leading to the desired C-8 alkoxymethyl 
derivatives llc-lle. Several C-8 acetoxymethyl, hydroxym­
ethyl or alkoxymethyl-substituted 3-aryl-4H-chromen-4-
ones possessed promising potency in the low micromolar 
range in a prostate cancer PC3 cell proliferation assay. 
In addition to isoflavonoids with various substituents 
described above, we prepared 3-aryl-4H-chromen-4-ones in 
which the substituents on C-6 and C-7 or the substituents on 
C-7 and C-8 together form a substituted or unsubstituted,
saturated or unsaturated, cyclic or polycyclic ring structure
including at least one oxygen atom. We further show the









The generation and Diels-Alder reactions of ortho-qui- 15 
none methides imbedded within a 3-aryl-4H-chromen-4-
ones platform was used to prepare ring-fused analogs of 
3-aryl-4H-chromen-4-ones having these cyclic arrange-
ments. In this regard, we synthesized various ring-fused
analogs such as the substituted 3-aryl-9,10-dihydropyrano 20 
HO 
[2,3- f ]chromen-4(8H)-ones 12 and 3-aryl-10-methyl-3,4-
dihydro-2H,6H-pyrano[3,2-g]chromen-6-ones 13 (Scheme
5).
Scheme 5. Representative ring-fused analogs of3-aryl-







The Betti reaction described earlier in this disclosure 
provided access to the desired progenitors of ortho-quinone 
methides that in turn led to ring-fused analogs of3-aryl-4H­
chromen-4-ones. Application of the Betti reaction to 7-hy­
droxyisoflavonoids 14 with bis(N,N-dimethylamino)meth­
ane in isopropanol at reflux provided regioselectively the 
C-8 substituted N,N-dimethylaminomethyl analogs 15
(Scheme 6) in good yield. The 7-hydroxy-8-methyisofla­
vonoids 16 gave, as expected, the isomeric C-6 analogs 17.
HO 
Scheme 6. Regioselective aminomethylation of7-hydroxylated 












a C-2 �X2 �H,X3 �OCH3 
b C-2 �H, X2 �x3 � OCH3 
c C-2 � H, X2, X3 � OCH,o 
d C-2 �H, X2, X3 � OCH,CH,o 




g C-2 � CH3, X2 � H, X3 � OCH3 
h C-2 � CH3, X
2 � X3 � OCH3 
i C-2 � CH3,X2 �H, X3 �CI 








Heating the N,N-dimethylaminomethyl-substituted iso­
flavonoids 15 or 17 generated the intermediate ortho-qui­
none methides 18 and 19, respectively (Scheme 7) that 
60 trapped various dienophiles, including 2,3-dihydrofuran, 
3,4-dihydro-2H-pyran, 3-(N,N-dimethylamino)-5,5-dim­
ethyl-2-cyclohexen-1-one, 1-morpholinocyclopentene, and 
1-morpholinocyclohexene, and led to Diels-Alder adducts
65 
20-26 (Schemes 8 and 9) in yields that varied with dieno-
phile reactivity (Table 2). 
US 9,718,799 B2 
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Scheme 7. Diels-Alder reactions ofN,N-dimethylaminomethyl-substituted 3-aryl-7-





a C-2 �X2 �H, X3 � OCH3 
bC-2 �H, X2 �x3 �OCH3 
c C-2 � H, X2, X3 � OCH20 
dC-2 �H, x2, x3 �ocH2CH2o 
e C-2 �X2 �H, X3 � Cl 
fC-2 �CH3, X
2 �x3 �H 
g C-2 � CH3, X
2 � H, X3 � OCH3 
h C-2 � CH3, X
2 � X3 � OCH3 
i C-2 � CH3,X
2 �H, X3 �CI 
















C-7a and bridgehead proton at C-1 Oa were consistent with
the structures of the cis-fused adducts 20 and 21 produced 40 
from the C-8 N,N-dimethylaminomethyl-substituted 3-aryl-
4H-chromen-4-one 15. The reaction of the isomeric C-6
N,N-dimethylaminomethyl-substituted 3-aryl-4H-chromen-
4-ones 17 also led to a cis-fused adduct 16. The Diels-Alder
reactions of 15 and 17 with 3-(N,N-dimethylamino)-5,5-
45 
dimethyl-2-cyclohexen-1-one led to initial adducts that suf­
fered thermal eliminations of dimethylamine to give the
isolated adducts 22 and 26, respectively, in excellent yield.
Scheme 8. Diels-Alder adducts 20-22 derived from thermal 
reactions of Betti bases 15 or 17 with various dienophiles. 
As noted in Table 2, a study of the reaction of 15a with the
50 
3-(N,N-dimethylamino )-5,5-dimethyl-2-cyclohexen-1-one
in various solvents led to the selection of refluxing N-N­
dimethylformamide as the optimal conditions for these
reactions. Finally, Diels-Alder reactions with 1-morpholino­
cyclopentene and 1-morpholinocyclohexene took a different 55 
turn and led to the adducts 23 and 24, respectively. The
mechanism leading to these adducts involved either an
initial cycloaddition, �-elimination of morpholine, and
hydrolysis of the intermediate enol ether or a nucleophilic
addition of the enamine to the ortho-quinone methide and 60 
subsequent imminium ion hydrolysis. The adduct, in the
case of 1-morpholinocyclopentene, adopted the open-chain
tautomer 23, and in the case of 1-morpholinocyclohexene,
the adduct preferred the cyclic hemiacetal 24. Hydrolysis of 65 
either the enol ethers or imminium ions leading to these 












a C-2 �X2 �H, X3 � OCH3 
bC-2 �H, X2 �x3 �OCH3 
c C-2 � H, X2, X3 � OCH,o 
dC-2 �H, X2, X3 �OCH2CH20 
e C-2 �X2 �H, X3 � Cl 
fC-2 �CH3, X2 �x3 �H
g C-2 � CH3, X2 � X3 � OCH3 
h C-2 � CH3, X2 � X3 � OCH3 
i C-2 � CH3,X2 �H, X3 �CI 
Scheme 9. More Diels-Alder adducts 23-26 derived 











a C-2 �X2 �H,X3 �OCH3 
b C-2 �H, X2 �x3 � OCH3 
c C-2 � H, X2, X3 � OCH20 
d C-2 �H, X2, X3 � OCH2CH20 









g C-2 � CH3, X2 � H, X3 � OCH3 
h C-2 � CH3, X2 � X3 � OCH3 
i C-2 � CH3,X2 �H, X3 �CI 
Proliferation studies using a prostate cancer PC3 cell line 
revealed that Diels-Alder adducts formed from 2,3-dihydro­
furan or 3,4-dihydro-2H-pyran with the ortho-quinone 
methide derived from C-8 N,N-dimethylaminomethyl-sub­
stituted isoflavonoids 15 produced the most active adducts 
25 20 and 21 (Table 3). In general, adducts 21 were more active 
than other adducts with a few exceptions. Among the 
exceptions to this generalization, Adducts 20a and 20e were 
comparable in activity to 21a and 21e. Similarly, adduct 24g 
23 30 
was slightly superior in activity to 21g. With respect to 
substituents on the isoflavonoid framework, those adducts 
bearing 3-( 4'-methoxyphenyl), 3-(3',4'-dimethoxyphenyl), 
3-(3',4'-methylenedioxyphenyl), or 3-( 4'-chlorophenyl) sub­




additional methyl group at C-2 had relatively little influence 
on activity with the exception of adduct 24g that was 
superior in activity to 24a. Most surprising, the adducts 
generated using 3-(N,N-dimethylamino )-5,5-dimethyl-2-cy­
clohexen-1-one were generally insoluble with the exception 
40 of adduct 22b that displayed 86% inhibition at 10 µM and 








Isolated yields of Diels-Alder adducts 20-26 from the reaction of 
dienophiles and ortho-guinone methides derived from 18 and 19. 
Solvent, Di els- Isolated 
Temperature Alder Yield 
strate Dienophile and Time Adduct (%) 
18a 2,3-dihydrofuran DMF, 154° C., 16 h 20a 70 
18a 3 ,-dihydro-2H-pyran DMF, 154° C., 16 h 21a 30 
18a 3-(N,N-dimethylamino )- 1,4-dioxane, 22a 81 
5,5-dimethyl-2- 100° c., 12 h 
cyclohexen-1-one 
18a 3-(N,N-dimethylamino )- toluene, 110° C. 22a 68 
5,5-dimethyl-2- 12 h 
cyclohexen-1-one 
18a 3-(N,N-dimethylamino )- 2-methoxyethanol, 22a 69 
5,5-dimethyl-2- 124° c., 8 h 
cyclohexen-1-one 
18a 3-(N,N-dimethylamino )- DMSO, 160° C., 22a 71 
5,5-dimethyl-2- 4 h  
cyclohexen-1-one 
18a 3-(N,N-dimethylamino )- DMF, 154° C., 4 h 22a 92 
5,5-dimethyl-2-
cyclohexen-1-one 
18a 1-morpholinocyclo- DMF, 154° C., 4 h 24a 91 
hexene 
18b 2,3-dihydrofuran DMF, 154° C., 16 h 20b 29 
18b 3 ,-dihydro-2H-pyran DMF, 154° C., 16 h 21b 55 




Isolated yields of Diels-Alder adducts 20-26 from the reaction of 
dienophiles and ortho-guinone methides derived from 18 and 19. 
Solvent, Di els- Isolated 
Temperature Alder Yield 




























3-(N,N-dimethylamino )- DMF, 154° C., 4 h 
5,5-dimethyl-2-
cyclohexen-1-one 
1-morpholinocyclo- DMF, 154° C., 4 h 
hexene 
2,3-dihydrofuran DMF, 154° C., 24 h 
3 ,-dihydro-2H-pyran DMF, 154° C., 24 h 
3-(N,N-dimethylamino )- DMF, 154° C., 4 h 
5,5-dimethyl-2-
cyclohexen-1-one 
1-morpholinocyclo- DMF, 154° C., 4 h 
pentene 
2,3-dihydrofuran DMF, 154° C., 24 h 
3 ,-dihydro-2H-pyran DMF, 154° C., 24 h 
2,3-dihydrofuran DMF, 154° C., 24 h 
3 ,-dihydro-2H-pyran DMF, 154° C., 24 h 
2,3-dihydrofuran DMF, 154° C., 24 h 
3 ,-dihydro-2H-pyran DMF, 154° C., 24 h 
3-(N,N-dimethylamino )- DMF, 154° C., 4 h 
5,5-dimethyl-2-
cyclohexen-1-one 
2,3-dihydrofuran DMF, 154° C., 16 h 
3 ,-dihydro-2H-pyran DMF, 154° C., 4 h 
3-(N,N-dimethylamino )- DMF, 154° C., 16 h 
5,5-dimethyl-2-
cyclohexen-1-one 
1-morpholinocyclo- DMF, 154° C., 4 h 
pentene 
1-morpholinocyclo- DMF, 154° C., 6 h 
hexene 
2,3-dihydrofuran DMF, 154° C., 24 h 
3 ,-dihydro-2H-pyran DMF, 154° C., 16 h 
1-morpholinocyclo- DMF, 154° C., 6 h 
pentene 
1-morpholinocyclo- DMF, 154° C., 4 h 
hexene 
2,3-dihydrofuran DMF, 154° C., 24 h 
3 ,-dihydro-2H-pyran DMF, 154° C., 24 h 
2,3-dihydrofuran DMF, 154° C., 24 h 
3-(N,N-dimethylamino )- DMF, 154° C., 4 h 
5,5-dimethyl-2-
cyclohexen-1-one 
























































Percent inhibition of proliferation in a prostate 
cancer PC3 cell assay by Diels-Alder adducts containing 
3-aryl-7-hydroxy-4H-chromen-4-one subunits. 
Isoflavonoid Inhibition 
Diels-Alder Substituents on Isoflavonoid at 10 µM 







62 ± 7 
20c H C6H3-3,4-(02CH2) 47 ± 4 







73 ± 6 
21b H C6H3-3,4-(0CH3)o 35 ± 10 
21c H C6H3-3,4-(02CH2) 68 ± 0.5 





-4-Cl 44 ± 4 
21g CH3 C6H4-4-0CH3 62 ± 0.4 
21h CH3 C6H3-3,4-(0CH3)o 44 ± 3 







)o 86 ± 1 
24a H C6H4-4-0CH3 30 ± 15 
24b H C6H3-3,4-(0CH3)o 56 ± 5 







Percent inhibition of proliferation in a prostate 
cancer PC3 cell assay by Diels-Alder adducts containing 
3-aryl-7-hydroxy-4H-chromen-4-one subunits. 
Isoflavonoid Inhibition 
Diels-Alder Substituents on Isoflavonoid at 10 µM 
Adduct C-2 C-3 (%) 
25a H C6H4-4-0CH3 78 ± 3 
25g CH3 C6H4-4-0CH3 61 ± 2 
In summary, a regioselective condensation of 3-aryl-7-
hydroxy-4H-chromen-4-ones 14 or 3-aryl-7-hydroxy-8-
methyl-4H-chromen-4-ones 16 with bis(N,N-dimethyl­
amino )methane in isopropanol at reflux provided the 
aminomethylated derivatives 15 or 17, respectively. Thermal 
eliminations of dimethylamine from these Betti bases 15 and 
16 generated ortho-quinone methide intermediates that 
trapped a variety of dienophiles to give various Diels-Alder 
adducts 20-26 in generally good yield. These adducts, par­
ticularly those derived from 2,3-dihydrofuran, 3,4-dihydro-
2H-pyran, or 3-(N,N-dimethylamino )-5,5-dimethyl-2-cy­
clohexen-1-one, displayed good activity in a proliferation
assay using a prostate cancer PC3 cell line. 
Another aspect of the present disclosure includes a phar­
maceutical composition of any one or more of the 3-aryl-
4H-chromen-4-ones of the present disclosure or one or more 
30 pharmaceutically acceptable salts thereof, e.g., one or more 
compounds of formula (I) and/or formula (II) and/or one or 
more pharmaceutically acceptable salts of compounds 
according to formulas (I) and/or (II), in combination with a 
pharmaceutically acceptable additive, e.g., a pharmaceuti-
35 cally acceptable carrier or excipient. In one aspect of the 
present disclosure, the pharmaceutical compositions com­
prise an effective amount of at least one 3-aryl-4H-chromen-
4-one or its pharmaceutically acceptable salt.
While it may be possible for compounds of the present
40 disclosure to be administered without an additive, it is 
preferable to present them as a pharmaceutical composition. 
According to a further aspect, the present disclosure pro­
vides a pharmaceutical composition comprising a compound 
or mixture of compounds of Formula (I) and/or Formula (II) 
45 or a pharmaceutically acceptable salt, solvate, or hydrate 
thereof, together with one or more pharmaceutically accept­
able additive, e.g., a pharmaceutically acceptable carrier or 
excipient and optionally one or more other therapeutic 
ingredients. The additive(s) must be "acceptable" in the 
50 sense of being compatible with the other ingredients of the 
formulation and not deleterious to the recipient thereof. The 
term "pharmaceutically acceptable carrier" includes 
vehicles and diluents. 
Another aspect of the present disclosure includes a 
55 method of treating prostate cancer. The method comprising 
administering to a patient in need of such treatment an 
effective amount of one or more of the 3-aryl-4H-chromen-
4-ones, including those with fused rings at C-6 and C-7 or
those with fused rings at C-7 and C-8 of the present
60 disclosure or pharmaceutically acceptable salt thereof or a 
pharmaceutical composition thereof. 
Accordingly, the compounds and/or compositions of the 
present disclosure are useful for treating animals, and in 
particular, mammals, including humans, as patients. Thus, 
65 humans and other animals, and in particular, mammals, 
suffering from hyperproliferative disorders, and in particu­
lar, prostate cancer, can be treated by administering to the 
US 9,718,799 B2 
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patient an effective amount of one or more of the isofla­
vonoids according to the present disclosure, or its derivative 
or a pharmaceutically acceptable salt thereof, optionally in 
a pharmaceutically acceptable additive, either alone, or in 
combination with other known pharmaceutical agents. 5 
Treatment according to the present disclosure can also be by 
administration of the compounds and/or compositions of the 
present disclosure in conjunction with other conventional 
cancer therapies, such as radiation treatment or surgery or 
administration of other anti-cancer agents. 10 
EXAMPLES 
20 
General Procedure for the Synthesis of Betti Bases 4a-4b 
and 5a-5b. 
To a suspension of 2 mmol of 3a-3b in 10 mL of 
1,4-dioxane was added 1.36 mL (10 mmol) of bis(N,N­
dimethylamino )methane. The mixture was refluxed for 
24-30 h, cooled and concentrated. The mixture of isomeric
Mannich bases 4a-4b and 5a-5b was chromatographed using
1 :50 methanol-dichloromethane.
6-[ (Dimethylamino )methyl]-5-hydroxy-7-methoxy-
3-(2-methoxyphenyl )-4 H-chromen-4-one ( 4a) 
Pale yellow solid ( 48% yield); mp 130-131 ° C.; IR (KBr): 
V
max
2937,2809,2759, 1659, 1585, 1457, 1282, 1222, 1120, The following examples are intended to further illustrate 
certain preferred embodiments of the invention and are not 
limiting in nature. Those skilled in the art will recognize, or 
be able to ascertain, using no more than routine experimen­
tation, numerous equivalents to the specific substances and 
procedures described herein. 
15 1078 cm-1 ; 1H NMR (400 MHz, CDC1
3
): Ii 2.31 (s, 6H,
N(CH
3)2), 3.52 (s, 2H, 6-CH2), 3.81 (s, 3H, 2'-0CH3), 3.92 
(s, 3H, 7-0CH
3
), 6.43 (s, lH, 8-H), 6.97-7.06 (m, 2H, 3', 
5'-H), 7.28-7.32 (m, lH, 6-H'), 7.35-7.42 (m, lH, 4'-H), 7.87 
(s, lH, 2-H), 13.12 ppm (s, lH, 5-0H); 13C NMR (101 MHz, 
Characterization: 1H and 13C NMR spectra were recorded 
2° CDC1
3
): ll 45.42, 49.70, 55.71, 56.17, 89.45, 106.06, 109.83, 
111.25, 119.66, 120.57, 121.37, 130.05, 131.58, 154.11, 
157.37, 157.45, 160.53, 164.22, 180.42 ppm; MS (CI): m/z 






: C, 67.59; 
on a Varian 500 (500 MHz/125 MHz), Varian 400 (400 





Structures were also confirmed with HMBC techniques. IR 
spectra were recorded on a Bruker Vertex 70 FT/IR spec- 25 
trometer. Melting points were determined using a Buchi 
B-535 apparatus and were uncorrected. Mass spectra were
obtained using an Agilent 1100 spectrometer in chemical
ionization mode. Chromatography was performed on Merck
silica gel 60.
H, 5.96; N, 3.94. Found: C, 67.87; H, 6.17; N, 4.17. 
6-[ (Dimethylamino )methyl]-5-hydroxy-7-methoxy-
3-( 4-methoxyphenyl )-4 H-chromen-4-one ( 4 b) 
Pale yellow solid (69% yield); mp 140-142° C.; IR (KBr): 
General Procedure for the Methylation of 3-Aryl-4H­
Chromen-4-0nes 3a and 3b. 
The procedure of Kim was repeated using 5 mmol of 3, 
2.07 g (15 mmol) of anhydrous potassium carbonate and 0.5 
mL (5.2 mmol) of dimethyl sulfate in 10 mL of acetone for 
6 h to afford the products 3a or 3b. See Kim et al. Org. Lett. 
2013, 15, 658. 
30 V
max
2933,2817,2757, 1653, 1610, 1514, 1254, 1221, 1123, 
832 cm-1 ; 1H NMR (400 MHz, CDC1
3




2), 3.53 (s, 2H, 6-CH2), 3.85 (s, 3H, 4'-0CH3), 3.92 
(s, 3H, 7-0CH
3
), 6.42 (s, lH, 8-H), 6.98 (d, 2H, 1=8.8 Hz, 
3', 5'-H), 7.46 (d, 2H, 1=8.8 Hz, 2', 6'-H), 7.88 (s, lH, 2-H), 
5-Hydroxy-7-methoxy-3-(2-methoxyphenyl)-4H­
chromen-4-one (3a) 
35 13.10 ppm (s, lH, 5-0H); 13C NMR (101 MHz, CDC1
3
): Ii 
45.38, 49.65, 55.27, 56.15, 89.41, 105.96, 109.81, 114.00, 
122.95, 123.77, 130.04, 152.32, 157.30, 159.67, 160.55, 







; C, 67.59; H, 5.96; N, 3.94. Found: 
40 C, 67.42; H, 6.14; N, 4.23. 
Pale yellow solid (89% yield); mp 153-154° C.; IR (KBr): 
v
max
2993, 2942, 2839, 1662, 1583, 1495, 1439, 1260, 1181, 
748 cm-1; 1H NMR (400 MHz, DMSO-d
6
): Ii 3.79 (s, 3H, 
2'-0CH
3
). 3.88 (s, 3H, 7-0CH
3
), 6.33 (s, lH, 6-H), 6.49 (s, 45 
lH, 8-H), 6.94-7.07 (m, 2H, 3',5'-H), 7.20-7.28 (m, lH, 
6'-H), 7.32-7.41 (m, lH, 4'-H), 8.06 (s, lH, 2-H), 12.76 ppm 
(s, lH, 5-0H); 13C NMR (100 MHz, DMSO-d
6
): Ii 55.54, 
56.06, 92.50, 98.06, 105.25, 111.29, 119.56, 120.13, 120.73, 
129.99, 131.55, 155.59, 157.42, 157.52, 161.59, 165.24, 50 







: C, 68.45; H, 4.73. Found: C, 68.12; H, 4.97. 
8-[ (Dimethylamino )methyl]-5-hydroxy-7-methoxy-
3-(2-methoxyphenyl )-4 H-chromen-4-one (Sa) 
Pale yellow solid (25% yield); mp 92-93° C.; IR (KBr): 
V
m
ax2924,2853, 1654, 1583, 1460, 1312, 1200, 1083, 1017 
cm-1 ; 1H NMR (400 MHz, CDC1
3





3.62 (s, 2H, 8-CH
2
), 3.82 (s, 3H, 2'-0CH
3
), 3.92 (s, 3H, 
7-0CH
3
), 6.45 (s, lH, 6-H), 6.98-7.06 (m, 2H, 3', 5'-H),
7.29-7.32 (m, lH, 6'-H), 7.36-7.42 (m, lH, 4'-H), 7.94 (s,
lH, 2-H), 13.12 ppm (s, lH, 5-0H); 13C NMR (101 MHz):
ll 43.66, 49.05, 55.70, 56.45, 95.23, 105.73, 111.21, 119.04,
120.57, 121.19, 130.23, 131.54, 154.62, 156.14, 157.40,
163.89, 164.02, 180.67 ppm; MS (CI): m/z 356.3 (MW,5-Hydroxy-7-methoxy-3-( 4-methoxyphenyl)-4H­






: C, 67.59; H, 5.96; N, 
3.94. Found: C, 67.83; H, 6.21; N, 4.13. 
Pale yellow solid (73% yield); mp 142-143° C.; IR (KBr): 
v
max
2964, 2936, 2833, 1658, 1618, 1579, 1516, 1244, 1192, 
1151, 1051 cm-1 ; 1H NMR (400 MHz, DMSO-d
6
): Ii 3.79 
(s, 3H, 4'-0CH
3
). 3.86 (s, 3H, 7-0CH
3), 6.41 (d, lH, 1=2.2 60 
Hz, 8-H), 6.65 (d, lH, 1=2.2 Hz, 6-H), 7.00 (d, 2H, 1=8.8 Hz, 
3', 5'-H), 7.51 (d, 2H, 1=8.7 Hz, 2',6'-H), 8.44 (s, lH, 2-H), 
12.92 ppm (s, lH, 5-0H); 13C NMR (101 MHz, DMSO-d
6
): 
Ii 55.14, 56.06, 92.40, 98.03, 105.37, 113.68, 122.13, 
122.73, 130.11, 154.61, 157.45, 159.17, 161.70, 165.21, 65 







: C, 68.45; H, 4.73. Found: C, 68.73; H, 4.94. 
8-[ (Dimethylamino )methyl]-5-hydroxy-7-methoxy-
3-( 4-methoxyphenyl )-4 H-chromen-4-one (Sb) 
Pale yellow solid (28% yield); mp 126-127° C.; IR (KBr): 
V
m
ax2934,2832, 1653, 1578, 1513, 1298, 1248, 1200, 1178, 
1039 cm-1 ; 1H NMR (400 MHz, CDC1
3
): Ii 2.30 (s, 6H, 
N(CH
3)2), 3.58 (s, 2H, 8-CH2), 3.84 (s, 3H, 4'-0CH3), 3.92 
(s, 3H, 7-0CH
3
), 6.44 (s, lH, 6-H), 6.98 (d, 2H, 1=8.8 Hz, 
3', 5'-H), 7.46 (d, 2H, 1=8.8 Hz, 2', 6'-H), 7.95 (s, lH, 2-H), 
13.13 ppm (s, lH, 5-0H); 13C NMR (101 MHz, CDC1
3
): Ii 
US 9,718,799 B2 
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45.21, 49.78, 55.23, 56.14, 95.06, 104.76, 105.48, 113.96, 
122.86, 122.88, 129.97, 152.94, 155.73, 159.62, 162.35, 







: C, 67.59; H, 5.96; N, 3.94. Found: 
C, 67.65; H, 5.77; N, 3.75. 
General Procedure for the Synthesis of Betti Bases 5c-5e. 
To a stirred suspension of 2 mmol of 3c-3e in 10 mL of 
isopropyl alcohol was added 0.3 mL (2.2 mmol) of bis(N, 
N-dimethylamino)methane. The mixture was heated at 80° 
C. for 4-6 h and was either cooled to induce crystallization 10 
or concentrated and then triturated with hexane to induce
crystallization. The compounds were recrystallized from
isopropanol-hexane.
22 
temperature. The mixture was diluted with water and the 




White solid (96% yield); mp 143-145° C.; IR (KBr): vmax 
2945, 2836, 1767, 1738, 1650, 1617, 1451, 1280, 1235, 
1127 cm-1 ; 1H NMR (400 MHz, CDC1
3
): ll 2.04 (s, 3H, C-6 
CH
2
0COC!b), 2.41 (s, 3H, C-5 OCOCH
3
), 3.78 (s, 3H, 
2'-0CH3), 3.96 (s, 3H, 7-0CH3), 5.21 (br. s, 2H, 6-CH2), 
6.80 (s, lH, 8-H), 6.93-7.03 (m, 2H, 3', 5'-H), 7.24-7.29 (m, 
8-[ (Dimethylamino )methyl]-7-hydroxy-3-(2-
methoxyphenyl)-4H-chromen-4-one (Sc) 
Pale yellow solid (91% yield); mp 120-121 ° C.; 1H NMR 
(400 MHz, CDC1
3




), 3.81 (s, 3H, 
2'-0CH3), 3.99 (s, 2H, 8-CH2), 6.89 (d, lH, 
3J=8.8 Hz, 6-H), 
6.96-7.06 (m, 2H, 3', 5'-H), 7.29-7.40 (m, 2H, 4', 6'-H), 7.88 
15 
lH, 6'-H), 7.32-7.38 (m, lH, 4'-H), 7.80 ppm (s, lH, 2-H); 
13C NMR (101 MHz, CDC1
3
): ll 20.85, 21.10, 54.69, 55.68, 
56.35, 97.13, 111.34, 111.69, 115.90, 120.52, 120.52, 
123.43, 129.85, 131.67, 150.12, 152.45, 157.40, 158.93, 
161.92, 169.32, 170.80, 174.02 ppm; MS (CI): m/z 413.2 
20 (MH






: C, 64.08; H, 4.89. 
Found: C, 64.27; H, 5.11. 
5-Acetoxy-6-( acetoxymethyl)-7-methoxy-3-( 4-
methoxyphenyl)-4H-chromen-4-one ( 6b)
White solid (97% yield); mp 167-169° C.; IR (KBr): vmax 
2962, 2834, 1734, 1629, 1513, 1453, 1248, 1182, 1123 
cm-1 ; 1H NMR (400 MHz, CDC1
3
): Ii 2.04 (s, 3H, C-6 
CH
2
0COC!b), 2.44 (s, 3H, C-5 OCOCH3), 3.83 (s, 3H, 
(s, lH, H-2), 8.19 (d, lH, 3J=8.8 Hz, 5-H), 12 ppm (br. s, lH, 
7-0H); 13C NMR (125 MHz, CDC13): ll 44.41, 54.87, 55.20,
107.27, 113.80, 115.44, 116.89, 124.22, 124.32, 126.67, 25 
130.00, 151.25, 154.96, 159.41, 163.97, 175.74 ppm; IR 
(KBr): vmax 3448, 2951, 1626, 1427, 1246, 1178, 1028 
cm-1; MS (CI): m/z 326.2 (MH+, 100). Anal. Calcd. for 
C
19H19N04: C, 70.14; H, 5.89; N, 4.30. Found: C, 70.27; H, 
5.77; N, 4.17. 30 4'-0CH3), 3.96 (s, 3H, 7-0CH3), 5.20 (s, 2H, 6-CH2), 6.80 
(s, lH, 8-H), 6.94 (d, 2H, J=8.8 Hz, 3', 5'-H), 7.39 (d, 2H, 
J=8.8 Hz, 2', 6'-H), 7.81 ppm (s, lH, 2-H); 13C NMR (101 
MHz, CDC1
3
): Ii 20.83, 21.08, 54.62, 55.25, 56.35, 97.06, 
111.53, 113.91, 116.01, 123.58, 125.95, 130.25, 150.18, 
8-[Dimethylamino )methyl]-7-hydroxy-3-( 4-
methoxypheny 1)-4 H-chromen-4-one ( 5d) 
35 150.85, 158.88, 159.58, 162.00, 169.38, 170.77, 174.40 







: C, 64.08; H, 4.89. Found: C, 63.89; H, 5.17. 
Pale yellow solid (83% yield); mp 174-176° C.; IR (KBr): 
vmax 3448, 2951, 1626, 1427, 1246, 1178, 1028 cm-1; 
1H 
NMR (400 MHz, CDC1
3
): ll 2.44 (s, 6H, N(CH
3)2), 3.85 (s, 
3H, 4'-0CH
3
), 3.99 (s, 2H, 8-CH
2
), 6.90 (d, lH, 3J=8.8 Hz, 
6-H), 6.97 (d, 2H, 3J=8.8 Hz, 3', 5'-H), 7.50 (d, 2H, 3J=8.8
Hz, 2', 6'-H), 7.89 (s, lH, 2-H), 8.14 (d, lH, 3J=8.8 Hz, 5-H), 40 
10.21 ppm (br. s, lH, 7-0H); 13C NMR (125 MHz, CDC1
3
): 
Ii 44.41, 54.87, 55.20, 107.27, 113.80, 115.44, 116.89,
124.22, 124.32, 126.67, 130.00, 151.25, 154.96, 159.41,
163.97, 175.74 ppm; MS (CI): m/z 326.1 (MW, 100). Anal.
Calcd. for C
19H19N04 : C, 70.14; H, 5.89; N, 4.30. Found: 45 




oxo-4H-chromen-6-yl]methyl acetate (6c) 
White solid (93% yield); mp 136-138° C.; IR (KBr): vmax 
3074, 2839, 1767, 1742, 1642, 1291, 1232, 1176 cm-1 ; 1H 
NMR ( 400 MHz, CDC1
3
): ll 2.09 (s, 3H, C-8 CH
2
0COC!___b), 
2.30 (s, 3H, 8-CH
3
), 2.41 (s, 3H, 7-0COCH
3
), 2.40 (s, 3H, 
C-7 OCOCH3), 3.85 (s, 3H, 4'-0CH3) 5.14 (s, 2H, 6-CH2), 
6.99 (d, 2H, 3J=8.8 Hz, 3', 5'-H), 7.51 (d, 2H, 3J=8.8 Hz, 2',
6'-H), 8.04 (s, lH, H-2), 8.26 ppm (s, lH, 5-H); 13C NMR
(100 MHz, CDC1
3
): Ii 9.44, 20.49, 20.82, 55.29, 61.28,
Pale yellow solid (91 % yield); mp 185-187° C. (decamp); 
50 113.90, 121.05, 122.21, 123.59, 124.80, 125.08, 126.11, 
129.93, 151.10, 152.36, 154.89, 159.54, 168.03, 170.35, 







: C, 66.66; H, 5.09. Found: C, 66.91; H, 4.89. 
IR (KBr): vmax 3450, 2958, 1626, 1603, 1255, 1176, 1016 
cm-1; 1H NMR (400 MHz, CDC1
3
): Ii 2.30 (s, 3H, 2-CH
3), 




), 3.84 (s, 3H, 4'-0CH
3
), 3.98 (s, 2H,
8-CH
2
), 6.85 (d, lH, 3J=8.8 Hz, 6-H), 6.97 (d, 2H, 3J=8.7 55 
Hz, 3', 5'-H), 7.20 (d, 2H, 3J=8.7 Hz, 2', 6'-H), 8.04 (d, lH,
3J=8.8 Hz, 5-H), 11.30 ppm (br. s, lH); 13C NMR (125
MHz, CDC1
3
): ll 19.28, 44.44, 54.85, 55.21, 106.83, 113.78,
115.03, 115.89, 122.51, 125.33, 126.74, 131.51, 154.68,
158.99, 161.76, 163.69, 176.47 ppm; MS (CI): m/z 340.1 60 






: C, 70.78; H, 6.24;
N, 4.13. Found: C, 70.91; H, 5.95; N, 4.33.
General Procedure for the Synthesis of Diacetates 6a-6b 
or 7a-7e. 
A mixture of Betti base 4a-4b or 5a-5e (2 mmol) and 200 65 
mg (2 mmol) of potassium acetate in 5 mL of acetic 
anhydride was refluxed for 5 min and cooled to room 
5-Acetoxy-8-( acetoxymethyl)-7-methoxy-3-(2-
methoxyphenyl)-4H-chromen-4-one (7 a)
White solid (98% yield); mp 116-118° C.; IR (KBr): vmax 
2946, 1759, 1652, 1537, 1389, 1254, 1157, 1022 cm-1 ; 1H 
NMR ( 400 MHz, CDC1
3
): ll 2.09 (s, 3H, C-8 CH
2
0COC!___b), 
2.40 (s, 3H, C-5 OCOCH
3
), 3.79 (s, 3H, 2'-0CH
3
), 3.96 (s, 
3H, 7-0CH
3
), 5.36 (s, 2H, 8-CH2), 6.67 (s, lH, 6-H), 
6.94-7.10 (m, 2H, 3', 5'-H), 7.24-7.29 (m, lH, 6'-H), 7.24-
7.28 (m, lH, 4'-H), 7.86 ppm (s, lH, 2-H); 13C NMR (101 
MHz, CDC1
3
): Ii 20.74, 20.98, 54.38, 55.39, 56.12, 103.49, 
109.19, 110.93, 111.38, 119.87, 120.18, 122.50, 129.53, 
131.34, 151.37, 152.36, 156.56, 156.99, 161.36, 169.18, 
US 9,718,799 B2 
23 







: C, 64.08; H, 4.89. Found: C, 64.32; H, 
5.07. 
24 
General Procedures for the Synthesis of Hydroxymethyl 
Derivatives Sa-Sb, 9a-9b and 9d-9e. 
To a solution of 6 or 7 (1 mmol) in 10 mL of 1,4-dioxane 
and 20 mL of0.2 M aqueous sulfuric acid. The mixture was 
5-Acetoxy-8-( acetoxymethyl)-7-methoxy-3-( 4-
methoxyphenyl)-4H-chromen-4-one (7b)
5 heated at 50-60° C. for 6-8 h. The mixture was cooled and 
diluted with water, and the resulting precipitate was col­
lected by filtration. The crude product was chromatographed 
using 1-20 methanol-dichloromethane and recrystallized 
from acetonitrile. 
White solid (88% yield); mp 124-126° C.; IR (KBr): v
max 
2943, 2840, 1763, 1740, 1645, 1515, 1411, 1304, 1247, 
1182, 1026 cm-1 ; 1H NMR (400 MHz, CDC1
3
): Ii 2.09 (s, 10 
3H, C-8 CH
2
0COC!b), 2.44 (s, 3H, C-5 OCOCH
3
), 3.84 (s, 
3H, 4'-0CH
3
), 3.97 (s, 3H, 7-0CH
3
), 5.37 (s, 2H, 8-CH
2
), 
6.68 (s, lH, 6-H), 6.96 (d, 2H, J=S.8 Hz, 3', 5'-H), 7.41 (d, 
2H, J=S.8 Hz, 2', 6'-H), 7.87 ppm (s, lH, 2-H); 13C NMR 
(101 MHz, CDC1
3
): Ii 20.95, 21.21, 54.57, 55.28, 56.41, 15 
103.95, 109.54, 111.61, 113.97, 123.49, 125.46, 130.27, 
151.07, 151.86, 156.91, 159.63, 161.83, 169.59, 171.02, 







: C, 64.08; H, 4.89. Found: C, 63.85; H, 4.61. 
5-Hydroxy-6-(hydroxymethyl)-7-methoxy-3-(2-
methoxyphenyl)-4H-chromen-4-one (Sa)
White solid (25%); mp 100-101 ° C.; IR (KBr): v
max 
2938, 
2837, 1654, 1583, 1494, 1283, 1220, 1129, 1076 cm-1 ; 1H 
NMR (400 MHz, CDC13): ll 3.81 (s, 3H, 2'-0CH3), 3.93 (s, 
3H, 7-0CH
3
), 4.81 (s, 2H, 6CH_
2
0H), 6.43 (s, lH, 8-H), 
6.94-7.08 (m, 2H, 3', 5'-H), 7.27-7.45 (m, 2H, 4', 6'-H), 7.88 
(s, lH, 2-H), 13.19 ppm (s, lH, 5-0H); 13C NMR (101 MHz, 
7 -( Acetoxy )-8-( acetoxymethy 1)-3-(2-methoxyphe­
nyl )-4 H-chromen-4-one (7c) 
2° CDC1
3
): Ii 53.71, 55.70, 56.07, 89.67, 106.18, 111.24 
(111.92), 119.37, 120.57, 121.38, 130.15, 131.54, 154.40, 
157.40, 157.57, 159.90, 163.20, 180.53 ppm; MS (CI): m/z 






: C, 65.85; H, 
White solid (98% yield); mp 122-124° C.; IR (KBr): v
max 
3076, 1759, 1741, 1660, 1255, 1236 and 1178 cm-1; 1H 25 
NMR (400 MHz, CDC1
3





2.40 (s, 3H, C-7 OCOCH
3
), 3.82 (s, 3H, 2'-0CH
3
) 5.40 (s, 
2H, 8-CH
2
), 6.97-7.07 (m, 2H, 3', 5'-H), 7.21 (d, lH, 3J=8.8 
Hz, 6-H), 7.30-7.35 (m, lH, 6'-H), 7.37-7.42 (m, lH, 4'-H), 
8.04 (s, lH, H-2), 8.35 ppm (d, lH, 3J=8.8 Hz, 5-H); 13C 30 
NMR (125 MHz, CDC1
3
): Ii 20.70, 20.79, 54.46, 55.29, 
114.03, 117.52, 120.31, 122.54, 123.47, 125.16, 128.06, 
130.03, 152.28, 153.65, 155.38, 159.77, 168.63, 170.52, 






7: C, 65.97; H, 4.75. Found: C, 65.83; H, 4.95. 35 
7-(Acetoxy)-8-( acetoxymethyl)-3-( 4-methoxyphe­
nyl)-4H-chromen-4-one (7d) 
Pale yellow solid (84% yield); mp 141-143° C.; IR (KBr): 40 
v
max 
3076, 1759, 1741, 1660, 1255, 1236 and 1178 cm-1; 1H 
NMR (400 MHz, CDC1
3
): ll 2.07 (s, 3H, C-8 CH
2
0COC!__b), 
2.40 (s, 3H, C-7 OCOCH
3
), 3.85 (s, 3H, 4'-0CH
3
) 5.39 (s, 
2H, 8-CH
2
), 6.99 (d, 2H, 3J=8.8 Hz, 3', 5'-H), 7.21 (d, lH, 
3J=8.8 Hz, 6-H), 7.51 (d, 2H, 3J=8.8 Hz, 2', 6'-H), 8.06 (s, 45 
lH, 2-H), 8.36 ppm (d, lH, 3J=8.8 Hz, 5-H); 13C NMR (125 
MHz, CDC1
3
): ll 20.69, 20.78, 54.45, 55.29, 114.02, 117.51, 
120.30, 122.53, 123.46, 125.15, 128.05, 130.02, 152.27, 
153.64, 155.37, 159.77, 168.62, 170.51, 175.59 ppm; MS 






: C, 50 




White crystals (77% yield); mp 142-144° C.; IR (KBr): 
v
max 
2922, 1765, 1737, 1645, 1223, 1199, 1180 cm-1; 1H 
NMR (400 MHz, CDC1
3
): ll 2.08 (s, 3H, C-8 CH
2
0COC!__b), 
2.36 (s, 3H, 2-CH
3
), 2.39 (s, 3H, C-7 OCOCH
3
), 3.85 (s, 3H, 
4'-0CH
3
), 5.40 (s, 2H, 8-CH
2
), 6.98 (d, 2H, 3J=8.3 Hz, 3', 60 
5'-H), 7.16 (d, lH, 3J=8.8 Hz, 6-H), 7.21 (d, 2H, 3J=8.3 Hz, 
2', 6'-H), 8.28 ppm (d, lH, 3J=8.8 Hz, 5-H); 13C NMR (125 
MHz, CDC1
3
): ll 19.45, 20.72, 20.78, 54.55, 55.24, 113.93, 
117.08, 119.84, 121.51, 123.30, 124.57, 127.94, 131.42, 
153.46, 154.92, 159.22, 163.21, 168.66, 170.50, 176.11 65 







: C, 66.66; H, 5.09. Found: C, 66.41; H, 5.27. 
4.91. Found: C, 65.93; H, 5.07. 
5-Hydroxy-6-(hydroxymethyl)-7-methoxy-3-( 4-
methoxyphenyl)-4H-chromen-4-one (Sb)
White solid (37% yield); mp 138-139° C.; IR (KBr): vhd 
max 2930, 2833, 1645, 1611, 1513, 1253, 1223, 1179, 836 
cm-1 ; 1 H NMR ( 400 MHz, CDC1
3
): ll 3.80 (s, 3H, 4'-0CH
3
), 
3.92 (s, 3H, 7-0CH
3
), 4.48 (s, 2H, 6-C�OH), 6.74 (s, lH, 
8-H), 6.96-7.05 (m, 2H, 3', 5'-H), 7.47-7.58 (m, 2H, 2', 6'-H),
8.48 (s, lH, 2-H), 13.23 ppm (s, lH, 5-0H); 13C NMR (101
MHz, CDC1
3
): Ii 53.68, 55.31, 56.08, 89.65, 106.12, 111.99,
114.07, 122.73, 123.84, 130.04, 152.57, 157.53, 159.80,
159.98, 163.34, 180.83 ppm; MS (CI): m/z (%): 329.2






: C, 65.85; H, 4.91.
Found: C, 65.56; H, 4.87.
7-Hydroxy-6-(hydroxymethyl)-3-( 4-methoxyphe­
nyl)-8-methyl-4H-chromen-4-one (Sc) 
White crystals (72% yield); mp 153-155° C.; IR (KBr): 
v
m
ax 2929, 1636, 1580, 1512, 1231, 1174, 1112, 1084 cm-1 ; 
1H NMR (400 MHz, DMSO-d
6





), 4.64 (s, 3H, 6-C�OH), 5.45 (s, 3H, 
6-CH
2
0H), 6.99 (d, 2H, 3J=8.7 Hz, 3', 5'-H), 7.52 (d, 2H,
3J=8.7 Hz, 2', 6'-H), 7.96 (s, lH, 5-H), 8.42 (s, lH, 2-H), 
9.73 ppm (s, lH, 7-0H); 13C NMR (100 MHz, DMSO-d
6
): 
ll 8.44, 55.11, 59.02, 111.01, 113.51, 116.50, 120.73, 122.66, 
124.32, 127.94, 129.97, 153.01, 154.21, 156.84, 158.77, 







: C, 69.22; H, 5.16. Found: C, 69.01; H, 5.45. 
5-Hydroxy-8-(hydroxymethyl)-7-methoxy-3-( 4-
methoxyphenyl)-4H-chromen-4-one (9b)
White solid (48% yield); mp 139-141 ° C.; IR (KBr): v
max 
2938, 2835, 1656, 1610, 1582, 151� 1250, 117� 1040, 831 
cm-1 ; 1HNMR(400 MHz, CDC1
3
): ll 3.85 (s, 3H, 4'-0CH
3
), 
3.96 (s, 3H, 7-0CH
3
), 4.86 (s, 2H, 8-C�OH), 6.44 (s, lH, 
6-H), 6.99 (d, 2H, 3J=8.8 Hz, 3', 5'-H), 7.46 (d, 2H, 3J=8.8
Hz, 2', 6'-H), 7.94 (s, lH, 2-H), 13.14 ppm (s, lH, 5-0H);
13C NMR (101 MHz, CDC1
3
): Ii 56.35, 55.36, 56.25, 95.22, 
105.56, 106.97, 114.08, 122.70, 123.29, 130.03, 152.66, 
154.91, 159.76, 163.03, 163.56, 181.11 ppm; MS (CI): m/z 
US 9,718,799 B2 
25 
329.2 (MH+, 100). Anal. Calcd. for C
18H1606: C, 65.85; H,
4.91. Found: C, 65.68; H, 5.11. 
7 -Hydroxy-8-(hydroxymethy 1)-3-(2-methoxyphe­
nyl )-4 H-chromen-4-one (9c) 
White crystals (63% yield); mp 163-165° C.; IR (KBr): 
v
max 
2953, 1627, 1603, 1441, 1267, 1237 cm-1; 1H NMR
( 400 MHz, DMSO-d
6
): ll 3.71 (s, 3H, 2'-0CH
3
), 4.72 (s, 2H, 
8-C!_hOH), 6.82 (d, lH, 3J=8.8 Hz, 6-H), 6.95-7.02 (m, lH, 10 
5'-H), 7.04-7.10 (m, lH, 3'-H), 7.19-7.25 (m, lH, 6'-H),
7.32-7.39 (m, lH, 4'-H), 7.75 (d, lH, 3J=8.8 Hz, 5-H), 8.12
ppm (s, lH, H-2); 13CNMR(125 MHz, DMSO-d
6
): ll 51.39,
55.13, 113.60, 114.59, 114.87, 116.60, 122.88, 124.25, 
125.91, 130.06, 153.10, 155.85, 158.94, 160.51, 174.86 15 




1405 : C, 68.45; H, 4.73. Found: C, 68.55; H, 4.93.
26 
109.02, 111.26, 119.49, 120.57, 121.46, 130.12, 131.53, 
154.23, 157.43, 157.99, 160.95, 164.22, 180.45; MS (CI): 
mlz 343.3 (MH+, 100). Anal. Calcd. for C
19H1806: C, 66.66;
H, 5.30. Found: C, 66.58; H, 5.17. 
5-Hydroxy-7-methoxy-6-(methoxymethyl)-3-( 4-
methoxyphenyl)-4H-chromen-4-one (1 Ob)
White solid (95% yield); mp 180-181 ° C.; IR (KBr): v
max 
2969, 2835, 1655, 1622, 1579, 1516, 1264, 1225, 1138, 
1097 cm-1 ; 1H NMR (400 MHz, DMSO-d
6





), 3.81 (s, 3H, 4'-0CH3), 3.93 (s, 3H, 7-0CH3), 




), 6.74 (s, lH, 8-H), 7.01 (d, 2H,
3J=8.8 Hz, 3', 5'-H), 7.53 (d, 2H, 3J=8.8 Hz, 2', 6'-H), 8.46
(s, lH, 2-H), 13.29 ppm (s, lH, 5-0H); 13C NMR (101 MHz,
DMSO-d
6
): Ii 55.16, 56.50, 57.28, 60.84, 90.31, 105.06,
108.41, 113.72, 122.33, 122.68, 130.17, 154.67, 157.45,
159.22, 159.97, 164.11, 180.40 ppm; MS (CI): m/z 343.2
7-Hydroxy-8-(hydroxymethyl)-3-( 4-methoxyphe­
nyl)-4H-chromen-4-one (9d) 20 
(MH+, 100). Anal. Calcd. for C
19H1806: C, 66.66; H, 5.30.
White crystals (69% yield); mp 150-152° C. (decamp); IR 
(KBr): v
m
ax 2953, 1627, 1603, 1441, 1267, 1237 cm-1; 1H
NMR (400 MHz, DMSO-d
6





), 4.91 (br s, lH, 8-CH
2
0!!), 6.95-7.05 (m, 3H, 25 
6, 3', 5'-H), 7.52 (d, 2H, 3J=8.8 Hz, 2', 6'-H), 7.93 (d, lH, 
3J=8.8 Hz, 5-H), 8.41 (s, lH, 2-H), 10.77 ppm (s, lH,
7-0H); 13C NMR (125 MHz, DMSO-d
6
): Ii 51.39, 55.13,
113.60, 114.59, 114.87, 116.60, 122.88, 124.25, 125.91, 
130.06, 153.10, 155.85, 158.94, 160.51, 174.86 ppm; MS 30 




C, 68.45; H, 4.73. Found: C, 68.72; H, 4.58. 
Found: C, 66.87; H, 5.56. 
7-Hydroxy-6-(methoxymethyl)-3-( 4-methoxyphe­
nyl)-8-methyl-4H-chromen-4-one (lOc) 
White crystals (68% yield); mp 143-145° C.; IR (KBr): 
v
m
ax 2929, 1636, 1580, 1512, 1231, 1174, 1112, 1084 cm-1;
1 H NMR ( 400 MHz, DMSO-d
6





0C�), 3.79 (s, 3H, 4'-0CH
3
), 4.52 (s, 3H, 
6-C!_hOCH
3
), 6.99 (d, 2H, 3J=8.8 Hz, 3', 5'-H), 7.51 (d, 2H,
3J=8.8 Hz, 2', 6'-H), 7.89 (s, lH, 5-H), 8.42 (s, lH, 2-H),
9.79 ppm (s, lH, 7-0H); 13C NMR (100 MHz, DMSO-d
6
): 
ll 8.61, 55.12, 57.79, 69.15, 111.47, 113.52, 116.49, 122.24,
122.72, 124.24, 124.26, 130.00, 153.12, 154.56, 157.15,7-Hydroxy-8-(hydroxymethyl)-3-( 4-methoxyphe­
nyl)-2-methyl-4H-chromen-4-one (9e) 35 158.81, 174.89 ppm; MS (CI): m/z 327.1 (MW, 100). Anal. 
White crystals (58% yield); mp 212-214° C. (decamp); IR 
(KBr): v
m
ax 2958, 1633, 1589, 1438, 1246, 1066 cm-1; 1H
NMR (400 MHz, DMSO-d
6
): ll 2.28 (s, 3H, 2-CH
3
), 3.79 (s, 
3H, 4'-0CH
3
), 4.71 (s, 2H, 8-CH
2
), 4.89 (br. s, lH, 8-CH
2
0 40 
!!), 6.92-7.05 (m, 3H, 6, 3', 5'-H), 7.19 (d, 2H, 3J=8.8 Hz, 2', 
6'-H), 7.82 (d, lH, 3J=8.8 Hz, 5-H), 10.68 ppm (s, lH, 
7-0H); 13C NMR (125 MHz, DMSO-d
6
): Ii 19.18, 51.48,
55.02, 113.43, 114.13, 114.55, 115.51, 121.43, 125.33, 
125.64, 131.62, 155.27, 158.47, 160.30, 162.37, 175.19 45 
ppm; MS (CI): m/z (%) 313.1 (MW, 100). Anal. Calcd. for 
C
18H1605 : C, 69.22; H, 5.16. Found: C, 68.95; H, 5.31. 
General Procedures for the Synthesis of Alkoxymethyl 
Derivatives lOa-lOb or lla-lle. 
A mixture of diacetate Sa-Sc or 9a-9f (2 mmol) and 0.1 50 
mL of concentrated hydrochloric acid in 10 mL of methanol 
was refluxed for 16-24 h. The mixture was cooled and 
diluted with water, and the resulting precipitate was col­
lected by filtration. The products were purified by chroma­
tography using 1 :20 methanol-dichloromethane. 55 
5-Hydroxy-7-methoxy-6-(methoxymethyl)-3-(2-
methoxypheny 1)-4 H-chromen-4-one ( 1 Oa)
Calcd. for C
19H1805: C, 69.93; H, 5.56. Found: C, 70.11; H,
5.38. 
5-Hydroxy-7-methoxy-8-(methoxymethyl)-3-(2-
methoxypheny I )-4 H-chromen-4-one (11 a)
White solid (28% yield); mp 154-155° C.; IR (KBr): v
max 
2922, 2835, 1664, 1558, 1377, 1311, 1285, 1239, 1095, 
1031 cm-1; 1H NMR (400 MHz, DMSO-d
6





), 3.74 (s, 3H, 2'-0CH
3
), 3.93 (s, 3H, 7-0CH
3
), 
4.51 (s, 2H, 8-C!_hOCH
3
), 6.61 (s, lH, 6-H), 6.98-7.05 (m,
lH, 5'-H), 7.07-7.15 (m, lH, 3'-H), 7.24-7.31 (m, lH, 6'-H),
7.36-7.44 (m, lH, 4'-H), 8.37 (s, lH, 2-H), 13.14 ppm (s, lH,
5-0H); 13C NMR (101 MHz, DMSO-d
6
): Ii 55.51, 56.49,
57.23, 60.89, 95.23, 104.03, 104.45, 111.23, 119.37, 120.04,
120.28, 129.88, 131.45, 155.31, 155.56, 157.29, 162.04,
163.65, 180.10 ppm; MS (CI): m/z 343.3 (MW, 100). Anal.
Calcd. for C




White solid (41% yield); mp 126-128° C.; IR (KBr): v
max 
White solid (53% yield); mp 123-124° C.; IR (KBr): v
max 
2934, 2880, 1656, 1585, 1494, 1450, 1284, 1220, 1137, 
1078 cm-1; 1H NMR (400 MHz, DMSO-d
6





), 3.75 (s, 3H, 2'-0CH
3
), 3.93 (s, 3H, 7-0CH
3
), 
4.41 (s, 2H, 6-C!_hOCH
3
), 6.78 (s, lH, 8-H), 6.94-7.09 (m,
2H, 3', 5'-H), 7.28-7.34 (m, lH, 6'-H), 7.35-7.43 (m, lH,
4'-H), 8.37 (s, lH, 2-H), 13.24 (s, lH, 5-0H); 13C NMR (101
MHz, CDCl
3
): Ii 55.70, 56.17, 58.14, 61.58, 89.56, 106.10,
60 2938, 2838, 1662, 1610, 1585, 1541, 1246, 1204, 1072, 
1042 cm-1 ; 1H NMR (400 MHz, DMSO-d
6
): ll 3.25 (s, 3H, 
8-CH
2
0CH_3), 3.79 (s, 3H, 4'-0CH3), 3.92 (s, 3H, 7-0CH3), 




), 6.60 (s, lH, 6-H), 7.01 (d, 2H,
J=S.8 Hz, 3', 5'-H), 7.52 (d, 2H, J=S.8 Hz, 2', 6'-H), 8.51 (s,
65 lH, 2-H), 13.24 ppm (s, lH, 5-0H); 
13C NMR (101 MHz, 
DMSO-d
6
): Ii 55.16, 56.53, 57.28, 60.92, 95.30, 103.96, 
104.65, 113.72, 121.85, 122.66, 130.17, 154.76, 155.38, 
US 9,718,799 B2 
27 
159.19, 162.36, 163.81, 180.64 ppm; MS (CI): m/z 343.3 
(MH+, 100). Anal. Calcd. for C
19H1806: C, 66.66; H, 5.30. 
Found: C, 66.43; H, 5.22. 
7 -Hydroxy-8-(methoxymethy 1)-3-(2-methoxyphe­
ny l)-4 H-chromen-4-one (llc) 
28 
crystallization. The Betti bases 14 and 16 were re-crystal­
lized from isopropanol-hexane. 
8-[(N,N-Dimethylamino )methyl]-7-hydroxy-3-( 4-
methoxyphenyl)-4H-chromen-4-one (15a) 
Pale yellow solid (83% yield); mp 174-176° C.; IR (KBr) 
v
m
ax 3448, 2951, 1626, 1427, 1246, 1178, 1028 cm-1 ; 1H 
NMR (400 MHz, CDCl
3




), 3.85 (s, 
White crystals (78% yield); mp 164-166° C.; IR (KBr): 
v
max 
2937, 1624, 1579, 1427, 1284, 1259 cm-1; 1H NMR 
( 400 MHz, DMSO-d
6




), 3.71 (s, 
3H, 2'-0CH3), 4.62 (s, 2H, 8-C!b0CH3), 6.91-7.02 (m, 2H, 
6, 5'-H), 7.04-7.10 (m, lH, 3'-H), 7.20-7.24 (m, lH, 6'-H), 
7.33-7.40 (m, lH, 4'-H), 7.82 (d, lH, 3J=8.8 Hz, 5-H), 8.17 
ppm (s, lH, H-2); 13C NMR (125 MHz, DMSO-d
6
): ll 55.07, 
57.45, 61.37, 111.24, 113.55, 114.45, 116.53, 122.95, 
124.13, 126.70, 130.01, 153.03, 156.16, 158.92, 161.10, 
174.71 ppm; MS (CI): m/z 313.2 (MW, 100). Anal. Calcd. 
for C
18H1605: C, 69.22; H, 5.16. Found: C, 68.88; H, 5.27. 
10 3H, 4'-0CH
3
), 3.99 (s, 2H, 8-CH
2
), 6.90 (d, lH, 3J=8.8 Hz,
6-H), 6.97 (d, 2H, 3J=8.8 Hz, 3', 5'-H), 7.50 (d, 2H, 3J=8.8
Hz, 2', 6'-H), 7.89 (s, lH, 2-H), 8.14 (d, lH, 3J=8.8 Hz, 5-H),




Ii 44.41, 54.87, 55.20, 107.27, 113.80, 115.44, 116.89, 
124.22, 124.32, 126.67, 130.00, 151.25, 154.96, 159.41, 
163.97, 175.74 ppm; MS (CI): m/z 326.1 (MW, 100). Anal. 
Calcd for C
19H19N04: C, 70.14; H, 5.89; N, 4.30. Found: C, 




White crystals (89% yield); mp 167-169° C. decamp; IR 
(KBr): v
m
ax 2937, 1624, 1579, 1427, 1284, 1259 cm-1 ; 1H 
NMR (400 MHz, DMSO-d
6





3.79 (s, 3H, 4'-0CH
3
), 4.62 (s, 2H, 8-C!b0CH
3
), 6.99 (d, 
2H, 3J=8.8 Hz, 3', 5'-H), 7.05 (d, lH, 3J=8.8 Hz, 6-H), 7.53 
(d, 2H, 3J=8.8 Hz, 2', 6'-H), 7.98 (d, lH, 3J=8.8 Hz, 5-H), 
8.40 (s, lH,2-H), 10.83 ppm (s, lH, 2-H) ppm; 13C NMR 
(125 MHz, DMSO-d
6
): Ii 55.07, 57.45, 61.37, 111.24, 30 
113.55, 114.45, 116.53, 122.95, 124.13, 126.70, 130.01, 
153.03, 156.16, 158.92, 161.10, 174.71 ppm; MS (CI): m/z 






: C, 69.22; H, 
5.16. Found: C, 69.01; H, 4.92. 
3-(3 ,4-Dimethoxyphenyl )-8-[ (N,N-dimethy !amino) 
methyl]-7-hydroxy-4H-chromen-4-one (15b) 
Pale yellow solid (77% yield); mp 154-155° C.; IR (KBr) 
v
m
ax 2948, 1636, 1602, 1517, 1266, 1145, 1024 cm-1 ; 1H 
NMR (400 MHz, CDCl
3





3.93 (2s, 6H, 3', 4'-0CH
3
), 3.99 (s, 2H, 8-CH
2
), 6.86-6.96 
(m, 2H, 6, 6'-H), 7.00-7.07 (m, lH, 5'-H), 7.18-7.23 (m, lH, 
2'-H), 7.92 (s, lH, 2-H), 8.13 (d, lH, 3J=8.8 Hz, 5-H), 9.79 
ppm (s, lH, 7-0H); 13C NMR (125 MHz, CDCl
3
) Ii 44.52, 
55.04, 55.88, 55.89, 107.40, 111.04, 112.46, 115.58, 116.93, 
120.90, 124.45, 124.70, 126.68, 148.64, 148.95, 151.44, 
154.93, 164.05, 175.86 ppm; MS (CI): m/z 356.2 (MW, 






: C, 67.59; H, 5.96; N, 
7-Hydroxy-8-(methoxymethyl)-3-( 4-methoxyphe­
nyl)-2-methyl-4H-chromen-4-one (lle) 
35 3.94. Found: C, 67.88; H, 5.97; N, 4.39. 
3-(1,3-Benzodioxol-5-yl)-8-[ (N,N-dimethylamino) 
methyl]-7-hydroxy-4H-chromen-4-one (15c) 
Pale yellow solid (73% yield); mp 160-161 ° C.; IR (KBr) 
v
m
ax 2960, 2987, 1639, 1488, 1425, 1246, 1017 cm-1; 1H 
NMR (400 MHz, CDCl
3




), 3.98 (s, 
2H, 8-CH2), 5.98 (s, 2H, 3',4'-0CH20), 6.80-7.00 (m, 3H, 6, 
5', 6'-H), 7.06-7.13 (m, lH, 2'-H), 7.86 (s, lH, 2-H), 8.11 (d, 
lH, 3J=8.8 Hz, 5-H), 9.95 ppm (s, lH, 7-0H); 13C NMR 
(125 MHz, CDCl
3
) Ii 44.60, 55.15, 101.13, 107.49, 108.34, 
109.78, 115.62, 116.94, 122.34, 124.61, 125.78, 126.78, 
147.56, 147.62, 151.46, 154.97, 164.12, 175.73 ppm; MS 
White crystals (89% yield); mp 215-217° C. decamp; IR 
(KBr): v
m
ax 2927, 1614, 1585, 1406, 1294, 1246, 1065 40 
cm-1; 1H NMR (400 MHz, DMSO-d6): Ii 2.27 (s, 3H,
2-CH
3
), 3.29 (s, 3H, 8-CH
2
0C!__h), 3.79 (s, 3H, 4'-0CH
3
), 
4.61 (s, 2H, 8-CH_20CH3), 6.98 (d, 2H, 
3J=8.8 Hz, 3', 5'-H),
7.00 (d, lH, 3J=8.8 Hz, 6-H), 7.20 (d, 2H, 3J=8.8 Hz, 2',
6'-H), 7.87 (d, lH, 3J=8.8 Hz, 5-H), 10.85 ppm (s, lH) ppm; 45 
13C NMR (125 MHz, DMSO-d
6
): Ii 19.13, 55.01, 57.48, 
61.40, 110.99, 113.41, 114.03, 115.43, 121.52, 125.21, 
126.48, 131.60, 155.70, 158.48, 160.89, 162.25, 175.08 
ppm; MS (CI): m/z 327.1 (MW, 100). Anal. Calcd. for 
C
19H1805 : C, 69.93; H, 5.56. Found: C, 70.23; H, 5.28. 50 (CI): m/z 340.3 (MH
+, 100). Anal. Calcd for C
19H1 7N05: C, 
67.25; H, 5.05; N, 4.13. Found: C, 67.48; H, 4.97; N, 4.39. Cell Proliferation Assay: 
PC3 prostate cancer cells were cultured in DMEM/F-12 
HAM Mixture (Sigma D8437), 10% Fetal Bovine Serum 
(Atlanta Biological S11150). Before the treatment, 3.5xl04 
cells per well were split into 12-well plates. After 24 h, 10 55 
µM of each compound was added to each well. DMSO was 
used as a control. This experiment was done in triplicate. 
Cell viability and number were analyzed using Vi-Cell XR 
Cell Viability Analyzer (Beckman Coulter). 
General Procedure for the Synthesis of Betti Bases 15 and 60 
17. 
3-(2,3-Dihydro-l ,4-benzodioxin-6-yl)-8-[ (N,N-dim­
ethy !amino )methy I]-7 -hydroxy-4 H-chromen-4-one 
(15d) 
Pale yellow solid (68% yield); mp 179-180° C.; IR (KBr); 
v
m
ax 3072, 2955, 1643, 1602, 1509, 1289, 1060, 1027 cm-1; 
1H NMR (400 MHz, CDCl
3







), 4.27 (s, 4H, 3',4'-0CH
2CH20), 6.88 (d, lH, 
3J=8.7 Hz, 6-H), 6.91 (d, lH, 3J=8.4 Hz, 8'-H), 7.02 (dd, lH, 
3J=8.7 Hz, 41=2.0 Hz, 7'-H), 7.09 (d, lH, 41=2.0 Hz, 5'-H),
7.86 (s, lH, 2-H), 8.11 (d, lH, 3J=8.7 Hz, 5-H), 10.04 ppm 
(s, lH, 7-0H); 13C NMR (125 MHz, CDCl
3
) ll 44.39, 54.63, 
To a stirred suspension of 14 or 16 (2 mmol) in 10 mL of 
isopropanol was added 0.3 mL (2.2 mmol, 1.1 eq) of 
bis(N,N-dimethylamino )methane at 70° C. The mixture was 
heated at 80° C. for 2 h and cooled to afford a precipitate that 
was collected by gravity filtration. In the absence of crys­
tallization, the residue was triturated with hexane to induce 
65 64.24, 64.38, 107.04, 115.54, 116.87, 117.16, 117.88, 
122.08, 124.27, 125.10, 126.94, 143.32, 143.57, 151.46, 
155.02, 164.03, 175.67 ppm; MS (CI): m/z 354.2 (MW, 
US 9,718,799 B2 
29 






: C, 67.98; H, 5.42; N, 
3.96. Found: C, 68.10; H, 5.67; N, 4.79. 
3-( 4-Chloropheny I )-8-[ (N,N-dimethy !amino) 
methyl]-7-hydroxy-4H-chromen-4-one (15e) 
Pale yellow solid (78% yield); mp 174-176° C.; IR (KBr) 
vmax 306l, 2958, 2838, 1881, 1632, 1590, 1466, 1378, 1257, 
1204, 1176, 1011, 824 cm-1; 1H NMR (400 MHz, CDCl
3
) 




), 3.97 (s, 2H, 8-CH
2
), 6.90 (d, lH, 
3J=8.8 Hz, 6-H), 7.36-7.41 (m, 2H, 3', 5'-H), 7.46-7.52 (m, 
2H, 2', 6'-H), 7.89 (s, lH, H-2), 8.11 (d, lH, 3J=8.8 Hz, 5-H), 
12.48 ppm (s, lH, 7-0H); 13C NMR (100 MHz, CDCl
3
) Ii 
44.59, 55.14, 107.55, 115.79, 116.89, 123.84, 126.75, 
128.60, 130.21, 130.51, 134.01, 151.79, 155.00, 164.32, 
175.37 ppm; MS (CI): m/z 330.2 (MW, 100), 332.2 (MW, 
28). Anal. Calcd for C
18H16CIN03: C, 65.56; H, 4.89; N, 
4.25. Found: C, 65.81; H, 5.07; N, 4.47. 
8-[ (N,N-Dimethylamino )methyl]-7-hydroxy-2-
methy 1-3-phenyl-4 H-chromen-4-one ( 15f) 
Pale yellow solid (81 % yield); mp 168-170° C.; IR (KBr) 
vmax 3052, 2952, 1633, 1599, 1399, 1287, 1258, 1018 cm-1 ; 
1H NMR (400 MHz, CDCl
3
) ll 2.29 (s, 3H, 2-CH
3





), 3.98 (s, 2H, 8-CH
2
), 6.84 (d, lH, 3J=8.8 Hz, 
6-H), 7.24-7.47 (m, SH, 3-Ph), 8.05 (d, lH, 3J=8.8 Hz, 5-H),
11.79 ppm (s, lH, 7-0H); 13C NMR (125 MHz, CDCl
3
) Ii
19.32, 44.41, 54.67, 106.69, 115.12, 115.83, 122.95, 126.83,
127.58, 128.24, 130.38, 133.17, 154.73, 161.90, 163.78,







: C, 73.77; H, 6.19; N, 4.53. Found: C, 73.92; H,
5.99; N, 4.43.
8-[(N,N-Dimethylamino )methyl]-7-hydroxy-3-( 4-
methoxypheny 1)-2-methy 1-4 H-chromen-4-one (15 g) 
Pale yellow solid (91 % yield); mp 185-187° C. decamp; 
30 
3-( 4-Chlorophenyl)-8-[ (N,N-dimethylamino) 
methyl]-7-hydroxy-2-methyl-4H-chromen-4-one 
(15i) 
Pale yellow solid (86% yield); mp 174-175° C.; IR (KBr) 
vmax 2974, 2835, 1631, 1407, 1371, 1285, 1258, 1014 cm-1 ; 
1H NMR (400 MHz, CDCl
3
) ll 2.29 (s, 3H, 2-CH
3





), 3.98 (s, 2H, 8-CH
2
), 6.86 (d, lH, 3J=8.8 Hz, 
6-H), 7.19-7.25 (m, 2H, 3', 5'-H), 7.36-7.42 (m, 2H, 2', 6'-H),
10 
8.03 (d, lH, 3J=8.8 Hz, 5-H), 12.14 ppm (s, 7-0H); 13C
NMR (100 MHz, CDCl
3
) Ii 19.32, 44.63, 55.24, 107.18,
115.29, 115.80, 121.99, 126.65, 128.54, 131.76, 131.88,
133.61, 154.63, 161.76, 163.99, 176.03 ppm; MS (CI): m/z




18CIN03: C, 66.38; H, 5.28; N, 4.07. Found: C, 66.10;
15 H, 4.99; N, 3.85.
6-[(N,N-Dimethylamino )methyl]-7-hydroxy-3-( 4-
methoxyphenyl)-8-methyl-4H-chromen-4-one (17a) 
20 To a suspension of2 mmol of16a in 10 mLof2-methoxy-
ethanol was added 1 mL (7.4 mmol) of bis(N,N-dimethyl­
amino)methane at 70° C. The mixture was heated at 124° C. 
for 16 h, cooled, and diluted with hexane. The precipitate 
was collected to afford 672 mg (99%) of 17 a as a yellow 
25 
solid: mp 182-183° C.; IR (KBr) vmax 3069, 2954, 2831, 
1627, 1512, 1461, 1369, 1290, 1223, 1176, 830 cm-1; 1H 
NMR (400 MHz, CDCl
3
) ll 2.32 (s, 3H, 8-CH
3





), 3.78 (s, 2H, 6-CH
2
), 3.84 (s, 3H, 4'-0CH
3
), 6.97 
(d, 2H, 3J=8.7 Hz, 3', 5'-H), 7.50 (d, 2H, 3J=8.7 Hz, 2', 6'-H), 
7.81 (s, lH, 5-H), 7.97 (s, lH, 2-H), 9.81 ppm (br s, lH, 
30 7-0H); 13C NMR (125 MHz, CDCl
3
) Ii 7.81, 44.21, 55.30,
62.37, 111.80, 113.88, 116.63, 120.31, 122.69, 124.02,
124.60, 130.07, 152.01, 155.76, 159.38, 161.30, 176.30







: C, 70.87; H, 6.24; N, 4.13. Found: C, 70.62; H,
35 6.43; N, 4.11.
6-[(N,N-Dimethylamino )methyl]-7-hydroxy-3-( 4-
methoxypheny 1)-2,8-dimethy 1-4 H-chromen-4-one 
(17g) 
IR (KBr) vmax 3450, 2958, 1626, 1603, 1255, 1176, 1016 40 
cm-1; 1H NMR (400 MHz, CDCl
3
): Ii 2.30 (s, 3H, 2-CH
3
), 




), 3.84 (s, 3H, 4'-0CH3), 3.98 (s, 2H,
8-CH
2
), 6.85 (d, lH, 3J=8.8 Hz, 6-H), 6.97 (d, 2H, 3J=8.7
Hz, 3', 5'-H), 7.20 (d, 2H, 3J=8.7 Hz, 2', 6'-H), 8.04 (d, lH, 
3J=8.8 Hz, 5-H), 11.30 ppm (br s, lH); 13C NMR (125 MHz, 45 
CDCl
3
): Ii 19.28, 44.44, 54.85, 55.21, 106.83, 113.78, 
115.03, 115.89, 122.51, 125.33, 126.74, 131.51, 154.68, 
158.99, 161.76, 163.69, 176.47 ppm; MS (CI): m/z 340.1 






: C, 70.78; H, 6.24; 
The procedure described for 17 a was repeated to afford 
509 mg of 17g as white solid (72% yield); mp 176-177° C.; 
IR (KBr) Vmax 3039, 2952, 2834, 1643, 1606, 1511, 1397, 
1239, 1158 cm-1; 1H NMR (400 MHz, CDCl
3
) ll 2.32 (s, 6H, 
2, 8-CH
3?, 2.36 (s, 6H, N(CH3).r),_ 3.76 (s, 2�, �-CH2), 3.85 (s, 3H, 4 -OCH
3
), 6.97 (d, 2H, J-8.7 Hz, 3 ,  5 -H), 7.21 (d, 
2H, 3J=8.7 Hz, 2', 6'-H), 7.74 ppm (s, lH, 5-H); 13C NMR 
(125 MHz, CDCl
3
) Ii 7.83, 19.43, 44.20, 55.23, 62.34, 
111.39, 113.77, 115.55, 119.84, 122.14, 122.62, 125.67, 
131.55, 155.31, 158.87, 161.02, 162.34, 176.92 ppm; MS 











C, 71.37; H, 6.56; N, 3.96. Found: C, 71.46; H, 6.31; N, 
4.17. 
General Procedure for the Synthesis of Diels-Alder 
Adducts 20 or 25. 
To a solution of 2 mmol of 15 or 17 in 10 mL of 
N,N-dimethylformamide was added 2 mL (26 mmol, 13 eq) 
of 2,3-dihydrofuran. The solution was refluxed for 24-40 h. 
The solvent and excess 2,3-dihydrofuran were evaporated in 
vacuo, and the residue was purified by chromatography 
60 using 1:50 methanol-dichloromethane to afford adducts 20 
or 25. 
Pale yellow solid (87% yield); mp 150-152° C.; IR (KBr) 
vmax 2995, 2841, 1635, 1516, 1393, 1262, 1020 cm-1; 1H 
NMR (400 MHz, CDCl
3
): Ii 2.31 (s, 3H, 2-CH
3





), 3.87, 3.91 (2s, 6H, 3', 4'-0CH
3
), 3.99 (s, 2H, 
8-CH
2
), 6.78-6.83 (m, 2H, 2', 6'-H), 6.85 (d, lH, 3J=8.8 Hz,
6-H), 6.92 (d, lH, 3J=8.7 Hz, 5'-H), 8.05 ppm (d, lH, 3J=8.8
Hz, 5-H); 13C NMR (125 MHz, CDCl
3
): Ii 19.39, 44.62,
55.24, 55.88, 55.89, 107.14, 111.11, 113.67, 115.11, 115.94,
122.76, 122.80, 125.84, 126.64, 148.50, 148.70, 154.61,
161.89, 163.78, 176.50 ppm; MS (CI): m/z 370.3 (MW, 65 






: C, 68.28; H, 6.28; N,
3.79. Found: C, 67.97; H, 6.14; N, 4.56.
3-( 4-Methoxyphenyl)-9, 10, 1 Oa, l 1-tetrahydro-4H, 
7aH-furo[2,3-b]pyrano[2,3-f]chromen-4-one (20a) 
Pale yellow solid (70% yield); mp 201-202° C.; IR (KBr) 
Vmax2903, 2844, 1643, 1610, 1510, 1435, 1295, 1242, 1205, 
US 9,718,799 B2 
31 
1052 cm-1; 1H NMR (400 MHz, CDC1
3
) ol.69-1.82 (m, lH, 
lOa-CH), 2.10-2.20 (m, lH, 10�-CH), 2.75-2.86 (m, lH, 
lOa-CH), 3.09 (dd, lH, 21=17.5 Hz, 31=6.2 Hz, lla-CH), 
3.19 (dd, lH, 21=17.5 Hz, 31=2.0 Hz, 11�-CH), 3.85 (s, 3H, 
4'-0Me), 4.01-4.10 (m, lH, 9a-CH), 4.16-4.24 (m, lH, 5 
9�-CH), 5.68 (d, lH, 31=4.2 Hz, 7a-CH), 6.94 (d, lH, 31=8.8 
Hz, 6-H), 6.96-7.00 (m, 2H, 3', H-5'-H), 7.48-7.54 (m, 2H, 
2', H-6'-H), 7.96 (s, lH, 2-H), 8.10 ppm (d, lH, 31=8.8 Hz, 
5-H); 13C NMR (400 MHz, CDC1
3
) o 19.46, 27.72, 36.27,
55.34, 68.45, 100.86, 107.02, 113.95, 115.55, 118.49, lO 
124.19, 124.79, 125.49, 130.11, 151.74, 155.39, 157.14, 







: C, 71.99; H, 5.18. Found: C, 72.17; H, 
4.92. 
3-(3,4-Dimethoxyphenyl)-9, 10, 1 Oa, 1 l-tetrahydro-









0), 5.68 (d, lH, 31=4.2 Hz, 7a-CH), 6.90-6.96 (m, 
2H, 6, 8'-H), 7.04 (dd, lH, 31=8.3, 41=2.0 Hz, 7'-H), 7.11 (d, 
lH, 31=2.0 Hz, 2'-H), 7.94 (s, lH, 7-H), 8.09 ppm (d, lH, 
31=8.8 Hz, 5-H); 13C NMR (400 MHz, CDC1
3
) o 19.45, 
27.70, 36.25, 64.32, 64.46, 68.45, 100.87, 107.05, 115.55, 
117.25, 117.94, 118.46, 122.13, 124.63, 125.09, 125.48, 
143.42, 143.69, 151.92, 155.35, 157.15, 175.79 ppm; MS 







69.84; H, 4.79. Found: C, 70.07; H, 4.95. 
3-( 4-Chlorophenyl)-9,10,1 Oa, 1 l-tetrahydro-4H,7aH­
furo[2,3-b ]pyrano[2,3-f]chromen-4-one (20e) 
Pale yellow solid (55% yield); mp 194-195° C.; IR (KBr) 
V
m
ax296l, 2899, 1637, 1598, 1492, 1438, 1377, 1244, 1092, 
1064, 1012, 819 cm-1 ; 1H NMR (400 MHz, CDC1
3
) o 
1.70-1.82 (m, lH, lOa-CH), 2.12-2.21 (m, lH, 10�-CH), 
2.77-2.86 (m, lH, lOa-CH), 3.09 (dd, lH, 21=17.5, 31=6.3 
Pale yellow solid (29% yield); mp 193-195° C.; IR (KBr) 
v
max
2900, 2843, 1637, 1607, 1510, 1437, 1398, 1290, 1244, 
1057, 1025, 840 cm-1 ; 1H NMR (400 MHz, CDC1
3
) o 
1.68-1.82 (m, lH, lOa-CH), 2.10-2.21 (m, lH, 10�-CH), 
2.75-2.86 (m, lH, lOa-CH), 3.09 (dd, lH, 21=17.5, 31=6.0 
Hz, lla-CH), 3.14-3.24 (m, lH, 11�-CH), 3.92 (s, 3H, 
3'-0Me), 3.93 (s, 3H, 4'-0Me), 4.01-4.12 (m, lH, 9a-CH), 
4.15-4.24 (m, lH, 9�-CH), 5.68 (d, lH, 31=4.l Hz, 7a-CH), 
6.91-6.98 (m, 2H, 6, 5'-H), 7.03-7.09 (m, lH, 6'-H), 7.22 (d, 
lH, 41=1.8 Hz, 2'-H), 7.99 (s, lH, 2-H), 8.10 ppm (d, lH,
31=8.9 Hz, 5-H); 13C NMR (400 MHz, CDC1
3
) o 19.47, 
27.71, 36.26, 55.96, 55.99, 68.46, 100.87, 107.03, 111.15, 
112.52, 115.65, 118.47, 121.01, 124.62, 124.85, 125.47, 
148.76, 149.10, 151.94, 155.38, 157.21, 176.00 ppm; MS 







69.46; H, 5.30. Found: C, 69.21; H, 5.01. 
20 Hz, lla-CH), 3.19 (dd, lH, 21=17.5, 31=2.0 Hz, 11�-CH), 
4.02-4.11 (m, lH, 9a-CH), 4.16-4.25 (m, lH, 9�-CH), 5.69 
(d, lH, 31=4.2 Hz, 7a-CH), 6.96 (d, lH, 31=8.9 Hz, 6-H), 
7.39-7.44 (m, 2H, 3', 5'-H), 7.49-7.55 (m, 2H, 2', 6'-H), 7.99 
(s, lH, 2-H), 8.10 ppm (d, lH, 31=8.9 Hz, 5-H); 13C NMR 
3-(1,3-Benzodioxol-5-yl)-9, 10, 1 Oa, 1 l-tetrahydro-
4H, 7 aH-furo[2,3-b ]pyrano[2,3-f]chromen-4-one 
(20c) 
25 (400 MHz, CDC1
3
) o 19.46, 27.70, 36.22, 68.48, 100.90, 
107.10, 115.83, 118.38, 124.19, 125.50, 128.65, 130.22, 
130.36, 134.15, 152.27, 155.42, 157.40, 175.50 ppm; MS 












Pale yellow solid (73% yield); mp 181-182° C.; IR (KBr) 
V
m
ax2966, 2900, 1634, 1607, 1579, 1510, 1437, 1398, 1244, 
1057, 840 cm-1; 1H NMR (400 MHz, CDC1
3
) o 1.70-1.83 
(m, lH, lOa-CH), 2.11-2.21 (m, lH, 10�-CH), 2.32 (s, 3H, 
2-CH
3
), 2.75-2.85 (m, lH, lOa-CH), 3.10 (dd, lH, 21=17.4,
40 31=6.l Hz, lla-CH), 3.21 (dd, lH, 21=17.4, 31=2.0 Hz, 
11�-CH), 4.01-4.10 (m, lH, 9a-CH), 4.16-4.23 (m, lH, 
9�-CH), 5.68 (d, lH, 31=4.2 Hz, 7a-CH), 6.91 (d, lH, 31=8.8 
Hz, 6-H), 7.27-7.30 (m, 2H, 2', 6'-H), 7.46-7.34 (m, 3H, 3', 
4', 5', H), 8.02 ppm (d, lH, 31=8.8 Hz, 5-H); 13C NMR (400 
Pale yellow solid (64% yield); mp 203-205° C.; IR (KBr) 
v
max
2986, 2903, 1641, 1600, 1490, 1435, 1245, 1226, 1056, 
1032 cm-1 ; 1H NMR (400 MHz, CDC1
3
) o 1.67-1.81 (m, 
lH, lOa-CH), 2.10-2.20 (m, lH, 10�-CH), 2.75-2.86 (m, 
lH, lOa-CH), 3.09 (dd, lH, 21=17.6, 31=6.2 Hz, lla-CH), 
3.19 (dd, lH, 21=17.6, 31=2.0 Hz, 11�-CH), 4.00-4.11 (m, 
lH, 9a-CH), 4.14-4.24 (m, lH, 9�-CH), 5.68 (d, lH, 31=4.2 
Hz, 7a-CH), 6.00 (s, 2H, OCH
2
0), 6.87 (d, lH, 31=8.0 Hz, 
7'-H), 6.94 (d, lH, 31=8.8 Hz, 6-H), 6.98 (dd, lH, 31=8.0, 
41=1.7 Hz, 6'-H), 7.10 (d, lH, 31=1.7 Hz, 4'-H), 7.95 (s, lH, 50 
2-H), 8.09 ppm (d, lH, 31=8.8 Hz, 5-H); 13C NMR (400
MHz, CDC1
3
) o 19.46, 27.71, 36.26, 68.46, 100.87, 101.16,
107.04, 108.36, 109.75, 115.63, 118.41, 122.35, 124.93,
125.50, 125.64, 147.63, 147.66, 151.91, 155.37, 157.21,







: C, 69.23; H, 4.43. Found: C, 69.52; H, 4.18.
45 MHz, CDC1
3
) o 19.39, 19.52, 27.76, 36.31, 68.44, 100.84, 
106.71, 115.15, 117.44, 123.38, 125.40, 127.68, 128.33, 
130.42, 133.20, 155.01, 157.00, 162.28, 176.34 ppm; MS 







75.43; H, 5.43. Found: C, 75.85; H, 5.72. 
3-( 4-Methoxyphenyl)-2-methyl-9,10,1 Oa, 1 l-tetra­
hydro-4H, 7 aH-furo[2,3-b ]pyrano[2,3-f]chromen-4-
one (20g) 
Pale yellow solid (62% yield); mp 227-229° C.; IR (KBr) 
V
m
ax2900, 2825, 1634, 1607, 1510, 1437, 1398, 1290, 1244, 
1057, 1025 cm-1; 1H NMR (400 MHz, CDC1
3
) o 1.68-1.82 
(m, lH, lOa-CH), 2.09-2.20 (m, lH, 10�-CH), 2.33 (s, 3H, 
2-CH
3
), 2.74-2.85 (m, lH, lOa-CH), 3.09 (dd, lH, 21=17.4,
3-(2,3-Dihydro-l ,4-benzodioxin-6-yl)-9, 10, 1 Oa, l 1-
tetrahydro-4H, 7aH-furo[2,3-b ]pyrano[2,3-f] 
chromen-4-one (20d) 
Pale yellow solid (75% yield); mp 188-189° C.; IR (KBr) 
v
max
2936, 2862, 1656, 1611, 1512, 1437, 1281, 1219, 1198, 
1138 cm-1; 1H NMR (400 MHz, CDC1
3
) o 1.68-1.82 (m, 
lH, lOa-CH), 2.09-2.20 (m, lH, 10�-CH), 2.75-2.86 (m, 
lH, lOa-CH), 3.09 (dd, lH, 21=17.4, 31=6.4 Hz, lla-CH), 
3.19 (dd, lH, 21=17.4, 31=2.0 Hz, 11�-CH), 3.99-4.09 (m, 
60 
31=6.2 Hz, lla-CH), 3.19 (dd, lH, 21=17.4, 31=1.6 Hz, 
11�-CH), 3.85 (s, 3H, 4'-0Me), 4.00-4.09 (m, lH, 9a-CH), 
4.15-4.22 (m, lH, 9�-CH), 5.67 (d, lH, 31=4.2 Hz, 7a-CH), 
6.90 (d, lH, 31=8.8 Hz, 6-H), 6.97 (d, 2H, 31=8.7 Hz, 3', 
5'-H), 7.21 (d, 2H, 31=8.7 Hz, 2', 6'-H), 8.01 ppm (d, lH, 
65 
31=8.8 Hz, 5-H); 13C NMR (400 MHz, CDC1
3
) o 19.41, 
19.53, 27.78, 36.33, 55.29, 68.43, 100.84, 106.69, 113.87, 
115.08, 117.43, 122.92, 125.31, 125.42, 131.55, 154.98, 
US 9,718,799 B2 
33 
156.94, 159.07, 162.22, 176.55 ppm; MS (CI): m/z 365.1 






: C, 72.51; H, 5.53. 
Found: C, 72.80; H, 5.82. 
3-(3,4-Dimethoxyphenyl)-2-methyl-9, 10, 1 Oa, 1 l­
tetrahydro-4H, 7aH-furo[2,3-b ]pyrano[2,3-f] 
chromen-4-one (20h) 
Pale yellow solid (56% yield); mp 217-219° C.; IR (KBr) 10 
v
max 
2936, 2859, 1634, 1602, 1578, 1506, 1436, 1386, 1242, 
1216, 1067 cm-1; 1H NMR (400 MHz, CDC1
3
) ll 1.69-1.82 
(m, lH, lOa-CH), 2.10-2.19 (m, lH, 10�-CH), 2.33 (s, 3H, 
2-CH
3
), 2.75-2.84 (m, lH, lOa-CH), 3.10 (dd, lH, 21=17.5,
31=6.l Hz, lla-CH), 3.20 (dd, lH, 21=17.5, 21=2.0 Hz, 15 
11�-CH), 3.88 (s, 3H, 3'-0Me), 3.92 (s, 3H, 4'-0Me), 
4.02-4.10 (m, lH, 9a-CH), 4.15-4.23 (m, lH, 9�-CH), 5.68 
(d, lH, 31=4.2 Hz, 7a-CH), 6.80-6.83 (m, 2H, 2', 6'-H), 6.90 
(d, lH, 31=8.8 Hz, 6-H), 6.93 (d, lH, 31=8.6 Hz, 5'-H), 8.02 
20 
ppm (d, lH, 31=8.8 Hz, 5-H); 13C NMR (400 MHz, CDC13) 
Ii 19.45, 19.53, 27.77, 36.32, 55.90, 55.92, 68.43, 100.85, 
106.68, 111.18, 113.68, 115.16, 117.42, 122.80, 123.14, 
125.41, 125.73, 148.60, 148.77, 154.99, 156.99, 162.44, 




2206 : C, 70.04; H, 5.62. Found: C, 69.85; H, 5.90. 
3-( 4-Chlorophenyl)-2-methyl-9, 10, 1 Oa, l 1-tetra­
hydro-4H, 7 aH-furo[2,3-b ]pyrano[2,3-f]chromen-4-
one (20i) 
30 
Pale yellow solid (60% yield); mp 266-268° C.; IR (KBr) 
v
max
297l, 2903, 1641, 1605, 1582, 1491, 1438, 1399, 1251, 
1088, 1068 cm-1; 1H NMR (400 MHz, CDC1
3
) ll 1.69-1.83 35 
(m, lH, lOa-CH), 2.11-2.20 (m, lH, 10�-CH), 2.32 (s, 3H, 
2-CH
3
), 2.75-2.85 (m, lH, lOa-CH), 3.10 (dd, lH, 21=17.4,
31=6.3 Hz, lla-CH), 3.20 (dd, lH, 21=17.4, 21=2.l Hz,
11�-CH), 4.02-4.11 (m, lH, 9a-CH), 4.16-4.23 (m, lH,
9�-CH), 5.68 (d, lH, 31=4.2 Hz, 7a-CH), 6.91 (d, lH, 31=8.8 40 
Hz, 6-H), 7.19-7.25 (m, 2H, 3', 5'-H), 7.38-7.44 (m, -2',
6'-H), 8.01 ppm (d, lH, 31=8.8 Hz, 5-H); 13C NMR (400
MHz, CDC1
3
) Ii 19.38, 19.52, 27.74, 36.28, 68.45, 100.87,
106.75, 115.32, 117.27, 122.34, 125.38, 128.59, 131.65, 
45 
131.86, 133.71, 155.01, 157.16, 162.32, 176.10 ppm; MS







: C, 68.39; H, 4.65. Found: C, 68.70; H,
4.87.
34 
(CI): m/z 365.3 (MH+, 100). Anal. Calcd for C
22
H
2005 : C, 
72.51; H, 5.53. Found: C, 72.80; H, 5.35. 
3-( 4-Methoxyphenyl)-2, l 1-methyl-6a, 7,8,9a-tetra­
hydro-4 H,6H-furo [2,3-b ]pyrano[3 ,2-g]chromen-4-
one (25g) 
Pale yellow solid (24% yield); mp 155-157° C.; IR (KBr) 
v
m
ax 2933, 2837, 1635, 1608, 1513, 1462, 1238, 1932 cm-1; 
1H NMR (400 MHz, CDC1
3
) ll 1.52-1.62 (m, lH, 7a-CH), 
2.02-2.12 (m, lH, 7�-CH), 2.33, 2.35 (2s, 3H, 3H, 2, 
ll-CH
3
), 2.80-2.91 (m, 2H, 6a-CH, 6a-CH), 3.09 (dd,
21=16.0, 31=5.7 Hz, lH, 6�-CH), 3.84 (s, 3H, 4'-0CH3), 
3.88-3.99 (m, 2H, 8-CH2), 5.83 (d, lH, 
31=5.3 Hz, 9a-CH), 
6.97 (d, 2H, 31=8.6 Hz, 3', 5'-H), 7.21 (d, 2H, 31=8.6 Hz, 2', 
6'-H), 7.82 ppm (s, lH, 5-H); 13C NMR (100 MHz, CDC13) 
Ii 8.24, 19.50, 26.54, 28.03, 37.76, 55.29, 68.32, 102.91, 
113.60, 113.88, 117.58, 120.15, 122.38, 123.09, 125.59, 
131.59, 154.37, 155.79, 159.00, 162.77, 176.94 ppm; MS 
(CI): m/z 365.3 (MH+, 100). Anal. Calcd for C
22
H
2005 : C, 
72.51; H, 5.53. Found: C, 72.80; H, 5.35. 
General Procedure for the Synthesis of Diels-Alder 
Adducts 21. 
To a solution of 2 mmol of 18 in 10 mL of N,N­
dimethylformamide was added 2 mL (22 mmol, 11 eq) of 
2H,3,4-dihydropyran. The solution was refluxed for 24-40 h. 
The solvent and excess 2,3-dihydrofuran were evaporated in 
vacuo, and the residue was purified by chromatography with 
1 :50 methanol-dichloromethane to afford 21. 
3-( 4-Methoxyphenyl)-10,11, 1 la,12-tetrahydro-4H, 
7aH,9H-dipyrano[2,3-b:2',3'-f]chromen-4-one (21a) 
Pale yellow solid (30% yield); mp 182-183° C.; IR (KBr) 
V
m
ax2966,2933, 1636, 1598, 1511, 1437, 1248, 1205, 1178, 
1090, 1029 cm-1; 1H NMR (400 MHz, CDC1
3
) ll 1.47-1.92 
(m, 4H, 10, ll-CH
2
), 2.24-2.40 (m, lH, lla-CH), 2.90 (dd, 
lH, 21=17.4 Hz, 31=4.2 Hz, 12a-CH), 3.01 (dd, lH, 21=17.4, 
31=6.l Hz, 12�-CH), 3.75-3.82 (m, lH, 9a-CH), 3.85 (s, 3H, 
4'-0Me), 3.95-4.09 (m, lH, 9�-CH), 5.44 (d, lH, 31=2.0 Hz, 
7a-CH), 6.93-7.02 (m, 3H, 6, 3', 5'-H), 7.50 (d, 2H, 31=8.7 
Hz, 2', 6'-H), 7.96 (s, lH, 2-H), 8.10 ppm (d, lH, 31=8.8 Hz, 
5-H); 13C NMR (400 MHz, CDC1
3
) Ii 23.17, 23.57, 24.02,
30.62, 55.33, 62.58, 96.94, 107.86, 113.94, 115.27, 118.45,
124.19, 124.79, 125.29, 130.13, 151.79, 155.37, 157.15,







: C, 72.51; H, 5.53. Found: C, 72.38; H,
5.67.
50 3-(3,4-Dimethoxyphenyl)-10, 11,1 la,12-tetrahydro-
3-( 4-Methoxyphenyl)-1 l-methyl-6a, 7 ,8,9a-tetra­
hydro-4 H,6H-furo [2,3-b ]pyrano [3 ,2-g]chromen-4-
one (25a) 
Pale yellow solid (27% yield); mp 155-157° C.; IR (KBr) 
v
max
2963, 2907, 1640, 1606, 1512, 1462, 1289, 1219, 1176, 
1056 cm-1; 1H NMR (400 MHz, CDC1
3
) Ii 1.53-1.67 (m, 
lH, 7a-CH), 2.00-2.14 (m, lH, 7�-CH), 2.33 (s, 3H, 
ll-CH
3
), 2.79-2.93 (m, 2H, 6a-CH, 6a-CH), 3.10 (dd,
21=16.4, 31=5.9 Hz, lH, 6�-CH), 3.83 (s, 3H, 4'-0CH3), 
3.88-3.98 (m, 2H, 8-CH
2
), 5.83 (d, lH, 31=5.l Hz, 9a-CH), 
6.98 (d, 2H, 31=8.8 Hz, 3', 5'-H), 7.51 (d, 2H, 31=8.8 Hz, 2', 
6'-H), 7.91 (s, lH, 5-H), 8.00 ppm (s, lH, 2-H); 13C NMR 
(100 MHz, CDC1
3
) ll 8.20, 26.53, 27.97, 37.67, 55.34, 68.33, 
102.87, 113.96, 118.62, 120.49, 123.20, 124.19, 124.49, 
130.11, 152.27, 154.78, 155.98, 159.49, 176.33 ppm; MS 
4H, 7aH,9H-dipyrano[2,3-b:2' ,3'-f]chromen-4-one 
(21b) 
Pale yellow solid (54% yield); mp 177-178° C.; IR (KBr) 
55 V
m
ax3076,2925, 1642, 1600, 1515, 1436, 1267, 1249, 1139, 
1090, 1023 cm-1; 1H NMR (400 MHz, CDC1
3
) ll 1.61-1.82 
(m, 4H, 10, ll-CH
2
), 2.27-2.37 (m, lH, lla-CH), 2.91 (dd, 
lH, 21=17.3, 31=4.l Hz, 12a-CH), 2.99 (dd, lH, 21=17.3, 
31=6.l Hz, 12�-CH), 3.76-3.83 (m, lH, 9a-CH), 3.92 (s, 3H, 
60 3'-0Me), 3.93 (s, 3H, 4'-0Me), 4.00-4.08 (m, lH, 9�-CH), 
5.45 (d, lH, 31=2.0 Hz, 7a-CH), 6.93 (d, lH, 31=8.3 Hz, 
5'-H), 6.98 (d, lH, 31=8.9 Hz, 6-H), 7.04 (dd, lH, 31=8.3, 
41=2.0 Hz, 6'-H), 7.22 (d, lH, 41=2.0 Hz, 2'-H), 7.99 (s, lH, 
2-H), 8.09 ppm (d, lH, 31=8.9 Hz, 5-H); 13C NMR (400
65 MHz, CDC1
3
) Ii 23.15, 23.56, 24.05, 30.64, 55.96, 55.98, 
62.61, 96.97, 107.89, 111.16, 112.55, 115.34, 118.46, 
121.02, 124.67, 124.83, 125.26, 148.76, 149.10, 151.96, 
US 9,718,799 B2 
35 
155.35, 157.22, 176.06 ppm; MS (CI): m/z 395.3 (MW, 






: C, 70.04; H, 5.62. Found: 
C, 70.27; H, 5.90. 
36 
1H NMR (400 MHz, CDC1
3
) Ii 1.66-1.81 (m, 4H, 10, 
ll-CH
2
), 2.32 (s, 4H, 2-CH
3
, lla-CH), 2.86-3.08 (m, 2H,
12a, 12�-CH), 3.75-3.86 (m, lH, 9a-CH), 4.01-4.11 (m,
lH, 9�-CH), 5.45 (d, lH, 31=2.4 Hz, 7a-CH), 6.94 (d, lH,
3-(1,3-Benzodioxol-5-yl)-10, 11, 11 a, l 2-tetrahydro-
4H, 7aH,9H-dipyrano[2,3-b:2' ,3'-f]chromen-4-one 
(21c) 
Pale yellow solid (25% yield); mp 179-181 ° C.; IR (KBr) 
v
max 
2925, 1637, 1599, 1434, 1247, 1142, 1033 cm-1; 1H 
NMR (400 MHz, CDC1
3
) ll 1.68-1.84 (m, 4H, 10, ll-CH
2
), 
2.25-2.37 (m, lH, lla-CH), 2.83-3.08 (m, 2H, 12a, 12�­
CH), 3.75-3.85 (m, lH, 9a-CH), 4.00-4.09 (m, lH, 9�-CH), 
5.44 (d, lH, 31=2.4 Hz, 7a-CH), 6.00 (s, 2H, OCH
2
0), 6.88 
5 31=8.8 Hz, 6-H), 7.28-7.32 (m, 2H, 2', 6'-H), 7.36 (t, lH, 
31=7.3 Hz, 4'-H), 7.44 (t, 2H, 31=7.3 Hz, 3', 5'-H), 8.02 ppm 
(d, lH, 31=8.9 Hz, 5-H); 13C NMR (400 MHz, CDC1
3
) Ii 
19.43, 23.24, 23.62, 24.09, 30.72, 62.58, 96.86, 107.44, 
114.77, 117.37, 123.30, 125.15, 127.59, 128.25, 130.36, 
10 133.16, 154.87, 156.87, 162.15, 176.26 ppm; MS (CI): m/z 






: C, 75.84; H, 
5.79. Found: C, 76.01; H, 5.95. 
(d, lH, 31=8.0 Hz, 7'-H), 6.95-7.01 (m, 2H, 6, 6'-H), 7.10 (d, 15 
lH, 31=1.7 Hz, 4'-H), 7.95 (s, lH, 2-H), 8.09 ppm (d, lH, 
31=8.8 Hz, 5-H); 13C NMR (400 MHz, CDC1
3
) Ii 23.19, 
23.58, 24.05, 30.63, 62.58, 96.91, 101.11, 107.82, 108.31, 
109.71, 115.29, 118.30, 122.31, 124.86, 125.23, 125.56, 
147.53, 147.55, 151.88, 155.25, 157.13, 175.82 ppm; MS 20 







69.84; H, 4.79. Found: C, 70.07; H, 4.61. 
3-( 4-Methoxyphenyl)-2-methyl-10,11, 1 la,12-tetra­
hydro-4H, 7aH,9H-dipyrano[2,3-b:2',3'-f]chromen-4-
one (21g) 
Pale yellow solid (34% yield); mp 199-200° C.; IR (KBr) 
V
m
ax293l,290l, 1637, 1606, 1510, 1440, 1397, 1255, 1243, 
1136, 1091, 1030 cm-1; 1H NMR (400 MHz, CDC1
3
) Ii 
1.61-1.82 (m, 4H, 10, ll-CH
2
), 2.28-2.35 (m, 4H, 2-CH
3
, 
lla-CH), 2.92 (dd, lH, 21=17.3, 31=4.2 Hz, 12a-CH), 3.00 
(dd, lH, 21=17.3, 31=6.3 Hz, 12�-CH), 3.76-3.83 (m, lH, 
9a-CH), 3.85 (s, 3H, 4'-0Me), 4.00-4.10 (m, lH, 9�-CH), 3-(2,3-Dihydro-l ,4-benzodioxin-6-yl)-10,11,l la,12-
tetrahydro-4H,7aH,9H-dipyrano[2,3-b:2',3'-f] 
chromen-4-one (21d) 
Pale yellow solid (36% yield); mp 160-162° C.; IR (KBr) 
25 5.44 (d, lH, 31=2.2 Hz, 7a-CH), 6.93 (d, lH, 31=8.8 Hz, 
6-H), 6.97 (d, 2H, 31=8.7 Hz, 3', 5'-H), 7.21 (d, 2H, 31=8.7
Hz, 2', 6'-H), 8.01 ppm (d, lH, 31=8.8 Hz, 5-H); 13C NMR
(400 MHz, CDC1
3
) Ii 19.41, 23.18, 23.58, 24.06, 30.69,
55.28, 62.59, 96.90, 107.48, 113.84, 114.76, 117.38, 122.88,V 
max 
2943, 2924, 2860, 1635, 1599, 1507, 1436, 1303, 1287, 
1249, 1091 cm-1; 1H NMR (400 MHz, CDC1
3
) ll 1.67-1.82 
(m, 4H, 10, ll-CH
2
), 2.27-2.35 (m, lH, lla-CH), 2.91 (dd, 
lH, 21=17.3, 31=4.l Hz, 12a-CH), 2.99 (dd, lH, 21=17.3, 
31=6.l Hz, 12�-CH), 3.75-3.83 (m, lH, 9a-CH), 4.00-4.09




0), 5.44 (d, 
lH, 31=2.4 Hz, 7a-CH), 6.93 (d, lH, 31=8.3 Hz, 8'-H), 6.97 35 
(d, lH, 31=8.9 Hz, 6-H), 7.03 (dd, lH, 31=8.3, 41=2.l Hz, 
7'-H), 7.10 (d, lH, 41=2.l Hz, 5'-H), 7.94 (s, lH, 2-H), 8.09 
ppm (d, lH, 31=8.9 Hz, 5-H); 13C NMR (400 MHz, CDC1
3
) 
30 125.19, 125.32, 131.55, 154.94, 156.91, 159.02, 162.25, 







: C, 73.00; H, 5.86. Found: C, 73.18; H, 6.02. 
Ii 23.19, 23.58, 24.01, 30.63, 62.56, 64.32, 64.46, 96.94, 
107.85, 115.27, 117.28, 117.96, 118.45, 122.18, 124.67, 40 
125.12, 125.32, 143.42, 143.68, 151.93, 155.33, 157.17, 







: C, 70.40; H, 5.14. Found: C, 70.15; H, 5.40. 
3-(3,4-Dimethoxyphenyl)-2-methyl-10, 11, 11 a, l 2-
tetrahydro-4H, 7 aH,9H-dipyrano[2,3-b:2' ,3'-f] 
chromen-4-one (21h) 
Pale yellow solid (15% yield); mp 209-210° C.; IR (KBr) 
v
m
ax 2934, 1636, 1581, 1513, 1438, 1394, 1258, 1138 cm-1; 
1H NMR (400 MHz, CDC1
3
) Ii 1.56-1.82 (m, 4H, 10, 
ll-CH
2
), 2.27-2.35 (m, 4H, 2-CH
3
, lla-CH), 2.98 (dd, lH,
21=17.2, 31=4.4 Hz, 12a-CH), 3.00 (dd, lH, 21=17.2, 31=6.3 
Hz, 12�-CH), 3.75-3.83 (m, lH, 9a-CH), 3.88 (s, 3H, 
3'-0Me), 3.92 (s, 3H, 4'-0Me), 4.00-4.10 (m, lH, 9�-CH), 
3-( 4-Chlorophenyl)-10,11,l la,12-tetrahydro-4H, 
7aH,9H-dipyrano[2,3-b:2',3'-f]chromen-4-one (21e) 
Pale yellow solid (19% yield); mp 195-197° C.; IR (KBr) 
v
max 
2930, 1643, 1597, 1437, 1256, 1206, 1094, 826 cm-1; 
45 5.44 (d, lH, 31=2.4 Hz, 7a-CH), 6.79-6.83 (m, 2H, 2', 6'-H), 
6.91-6.95 (m, 2H, 6, 5'-H), 8.02 ppm (d, lH, 31=8.8 Hz, 
5-H); 13C NMR (400 MHz, CDC1
3
) ll 19.45, 23.17, 23.57,
24.08, 30.69, 55.90, 55.91, 62.61, 96.93, 107.51, 111.17,
113.68, 114.86, 117.37, 122.81, 123.12, 125.19, 125.76,
50 148.58, 148.76, 154.97, 156.99, 162.51, 176.68 ppm; MS 







70.58; H, 5.92. Found: C, 70.69; H, 6.17. 
1H NMR (400 MHz, CDC1
3
) Ii 1.67-1.84 (m, 4H, 10, 
ll-CH
2
), 2.28-2.38 (m, lH, lla-CH), 2.85-3.07 (m, 2H,
12a, 12�-CH), 3.76-3.85 (m, lH, 9a-CH), 3.99-4.11 (m,
lH, 9�-CH), 5.45 (d, lH, 31=2.4 Hz, 7a-CH), 6.99 (d, lH,
31=8.8 Hz, 6-H), 7.42 (d, 2H, 31=8.7 Hz, 3', 5'-H), 7.52 (d,
2H, 31=8.7 Hz, 2', 6'-H), 7.99 (s, lH, 2-H), 8.09 ppm (d, lH, 55 
31=8.9 Hz, 5-H); 13C NMR (400 MHz, CDC1
3
) Ii 23.20,
23.59, 24.05, 30.61, 62.60, 96.93, 107.89, 115.47, 118.33,
124.13, 125.25, 128.60, 130.16, 130.32, 134.06, 152.16,
155.28, 157.28, 175.27 ppm; MS (CI): m/z 369.2 (MW,






: C, 60 
68.39; H, 4.65. Found: C, 68.17; H, 4.43.
2-Methyl-3-phenyl-10,11,l la,12-tetrahydro-4H, 7aH,
9H-dipyrano[2,3-b:2',3'-f]chromen-4-one (21f)
Pale yellow solid (33% yield); mp 165-167° C.; IR (KBr) 
v
max 




Pale yellow solid (15% yield); mp 205-206° C.; IR (KBr) 
V
m
ax2927, 1635, 1605, 1439, 1398, 1257, 1139, 1094, 895 
cm-1; 1H NMR (400 MHz, CDC1
3
) ll 1.82-1.64 (m, 4H, 10,
ll-CH
2
), 2.28-2.37 (m, 4H, 2-CH
3
, lla-CH), 2.84-3.07 (m,
2H, 12a, 12�-CH), 3.75-3.84 (m, lH, 9a-CH), 4.00-4.10
(m, lH, 9�-CH), 5.44 (d, lH, 31=2.5 Hz, 7a-CH), 6.95 (d,
lH, 31=8.8 Hz, 6-H), 7.20-7.25 (m, 2H, 2', 6'-H), 7.38-7.43
65 (m, 2H, 3', 5'-H), 8.01 ppm (d, lH, 
31=8.8 Hz, 5-H); 13C 
NMR (400 MHz, CDC1
3
) Ii 19.38, 23.12, 23.51, 24.03, 
30.60, 62.59, 96.90, 107.55, 115.03, 117.15, 122.27, 125.16, 
US 9,718,799 B2 
37 
128.57, 131.59, 131.83, 133.67, 154.96, 157.15, 162.44, 
176.20 ppm; MS (CI): m/z 383.2 (MW, 100), 385.2 (MW, 






: C, 72.03; H, 5.22. Found: 
C, 72.31; H, 5.43. 
General Procedure for the Synthesis of Diels-Alder 5 
Adducts 22 and 26. 
To a solution of 1 mmol of 18 or 19 was added 1.25 mmol 
(1.25 eq) of 3-(N,N-dimethylamino )-5,5-dimethylcyclohex-
2-en-1-one in 10 mL ofN,N-dimethylformamide. The solu­
tion was refluxed for 4 h. The mixture was diluted with 20 10 
mL of methanol, and the precipitate was collected by filtra­
tion and re-crystallized from N,N-dimethylformamide­
methanol to afford 22 or 26.
38 







: C, 72.11; H, 4.84. Found: C, 72.29; H, 
5.11. 
2,9 ,9-trimethyl-3-phenyl-8,9, 10, l 2-tetrahydro-4H, 
11 H-pyrano[2,3-a ]xanthene-4, 11-dione (22f) 
Beige solid (84% yield); mp 265-266° C.; IR (KBr) vmax 
3047, 2947, 2885, 1646, 1590, 1390, 1235, 1215, 700 cm-1; 
1 H NMR ( 400 MHz, CDC1
3
) Ii 1.17 (s, 6H, 9-CH
3
), 2.35 (s, 
3H, 2-CH
3
), 2.40 (s, 2H, 10-CH
2





), 7.01 (d, lH, 3J=8.8 Hz, 6-H), 7.26-7.30 (m, 
2H, 2', 6'-H), 7.35-7.40 (m, lH, 4'-H), 7.41-7.47 (m, 2H, 3', 
5'-H), 8.08 ppm (d, lH, 3J=8.8 Hz, 5-H); 13C NMR (100 
3-( 4-Methoxyphenyl)-9 ,9-dimethyl-8,9, 10, l 2-tetra­




) Ii 16.48, 19.55, 28.42, 32.20, 41.22, 50.64,
108.34, 109.56, 113.99, 120.04, 123.73, 125.56, 127.85, 
128.41, 130.34, 132.82, 152.94, 154.29, 163.30, 164.46, 







: C, 77.70; H, 5.74. Found: C, 77.92; H, Beige solid (92% yield); mp 223-225° C.; IR (KBr) v max 
2949, 1647, 1606, 1511, 1438, 1237, 1032 cm-1; 1H NMR 
(400 MHz, DMSO-d
6
) Ii 1.10 (s, 6H, 9-CH
3
), 2.33 (s, 2H, 
10-CH
2
), 2.53 (2, 2H, 8-CH
2





), 7.01 (d, 2H, 3J=8.6, 3', 5'-H), 7.18 (d, lH, 11,
3J=8.8, 6-H), 7.54 (d, 2H, 3J=8.6, 2', 6'-H), 8.00 (d, 2H, 25 





1:1) Ii 16.01, 27.89, 31.67, 40.57,
50.07, 54.80, 107.61, 109.39, 113.36, 113.84, 120.34, 
123.22, 124.36, 124.84, 129.51, 151.86, 152.47, 153.99, 
159.01, 163.63, 174.96, 196.87 ppm; MS (CI): m/z 403.2 30 






: C, 74.61; H, 5.51. 
Found: C, 74.47; H, 5.27. 
20 5.88. 
3-( 4-Methoxyphenyl)-2,9,9-trimethyl-8,9, 10, 12-
tetrahydro 4H, 11H-pyrano[2,3-a]xanthene-4,1 l­
dione (22g) 
Beige solid (90% yield); mp 236-237° C.; IR (KBr) v
max 
2958, 2890, 1653, 1586, 1515, 1440, 1393, 1239, 1174, 
1026 cm-1; 1H NMR (400 MHz, CDC1
3
) Ii 1.14 (s, 6H, 
9-CH
3
), 2.32 (s, 3H, 2-CH
3





), 3.62 (s, 2H, 12-CH
2
), 3.82 (s, 3H, 4'-0CH3), 
6.92-6.99 (m, 3H, 6, 3', 5'-H), 7.15-7.21 (m, 2H, 2', 6'-H),
8.04 ppm (d, lH, 3J=8.8 Hz, 5-H); 13C NMR (100 MHz,
CDC1
3
) Ii 16.47, 19.56, 28.42, 32.19, 41.23, 50.65, 55.28,
108.36, 109.52, 113.92, 113.93, 120.02, 123.28, 124.91,3-(3,4-Dimethoxyphenyl)-9 ,9-dimethyl-8,9, 10, l 2-
tetrahydro-4H, 11 H-pyrano[2,3-a ]xanthene-4, 11-
dione (22b) 
Beige solid (75% yield); mp 196-198° C.; IR (KBr) vmax 
2955, 1654, 1640, 1516, 1440, 1261, 1237, 1195 cm-1; 1H 
35 125.56, 131.50, 152.90, 154.26, 159.17, 163.25, 164.46, 







: C, 74.98; H, 5.81. Found: C, 74.70; H, 
6.10. 
40 
NMR (400 MHz, CDC1
3
) ll 1.17 (s, 6H, 9-CH
3
), 2.39 (s, 2H, 
10-CH
2
), 2.50 (s, 2H, 8-CH
2
), 3.65 (s, 2H, 12-CH2), 3.93,
3.94 (2s, 6H, 3', 4'-0CH
3
), 6.94 (d, lH, 3J=8.3 Hz, 5'-H),
7.02-7.10 (m, 2H, 6, 6'-H), 7.21 (d, lH, 4J=l.8 Hz, 2'-H),
8.04 (s, lH, 2-H), 8.15 ppm (d, lH, 3J=8.3 Hz, 5-H); 13C 45 
NMR (400 MHz, CDC1
3
) Ii 16.51, 28.42, 32.20, 41.17,
50.60, 55.94, 55.96, 108.31, 109.99, 111.18, 112.39, 114.45,
121.02, 121.07, 124.17, 125.20, 125.60, 148.80, 149.24,
152.51, 153.12, 154.62, 164.28, 175.76, 197.69 ppm; MS






: C, 50 
72.21; H, 5.59. Found: C, 72.49; H, 5.22.
3-( 4-Methoxyphenyl)-9,9, 12-trimethyl-6,8,9, 1 O­
tetrahydro-4H, 7H-pyrano[3,2-b ]xanthene-4, 7-dione 
(26a) 
Beige solid (80% yield); mp 230-232° C.; IR (KBr) vmax 
3079, 2958, 2835, 1645, 1612, 1514, 1463, 1391, 1296, 
1220, 1179 cm-1; 1H NMR(400 MHz, CDC1
3
) ll 1.16 (s, 6H, 
9-CH
3
), 2.35 (s, 2H, 8-CH
2





), 3.62 (s, 2H, 6-CH2), 3.84 (s, 3H, 4'-0CH3), 
6.97 (d, 2H, 3J=8.8 Hz, 3', 5'-H), 7.50 (d, 2H, 3J=8.8 Hz, 2',
6'-H), 7.96 (s, lH, 5-H), 8.00 ppm (s, lH, 2-H); 13C NMR
(100 MHz, CDC1
3
) ll 8.32, 20.97, 28.45, 32.20, 41.29, 50.62,
55.34, 109.16, 113.99, 114.18, 118.85, 120.88, 124.05,
124.16, 124.49, 130.05, 151.43, 152.48, 153.96, 159.62,
163.91, 175.92, 197.56 ppm; MS (CI): m/z 417.3 (MW,
3-(1,3-Benzodioxol-5-yl)-9 ,9-dimethyl-8,9, 10, l 2-
tetrahydro-4H, 11 H-pyrano[2,3-a ]xanthene-4, 11-






: C, 74.98; H, 5.81. Found: 
Beige solid (80% yield); mp 258-260° C.; IR (KBr) vmax 
2950, 2897, 1649, 1599, 1429, 1240, 1194, 1037 cm-1; 1H 
NMR (400 MHz, CDC1
3
) ll 1.17 (s, 6H, 9-CH
3
), 2.39 (s, 2H, 
10-CH
2
), 2.50 (s, 2H, 8-CH
2
), 3.64 (s, 2H, c, 12-CH
2
), 6.00 60 
(s, 2H, OCH
2
0), 6.88 (d, lH, 3J=8.0 Hz, 5'-H), 6.99 (dd, lH,
4J=l.7 Hz, 3J=8.0 Hz, 6'-H), 7.05 (d, lH, 3J=8.8 Hz, 6-H),
7.10 (d, lH, 4J=l.7 Hz, 2'-H), 8.00 (s, lH, 2-H), 8.15 ppm
(d, lH, 3J=8.8 Hz, 5-H); 13C NMR (100 MHz, CDC13) Ii
16.52, 28.43, 32.21, 41.19, 50.61, 101.22, 108.33, 108.45, 65 
109.71, 110.01, 114.46, 120.99, 122.42, 125.23, 125.32,
125.69, 147.74, 147.81, 152.49, 153.15, 154.65, 164.28,
C, 75.22; H, 5.64. 
3-( 4-Methoxyphenyl)-2,9 ,9, l 2-tetramethyl-6,8,9, 1 O­
tetrahydro-4H, 7H-pyrano[3,2-b ]xanthene-4, 7-dione 
(26g) 
Beige solid (72% yield); mp 270-272° C.; IR (KBr) vmax 
2954, 2878, 1642, 1609, 1395, 1238, 1220, 1142 cm-1 ; 1H 
NMR (400 MHz, CDC1
3
) ll 1.16 (s, 6H, 9-CH
3
), 2.34 (s, 3H, 
2-CH
3
), 2.36 (s, 2H, 8-CH
2





), 3.61 (s, 2H, 6-CH
2
), 3.85 (s, 3H, 4'-0CH
3
), 
6.97 (d, 2H, 3J=8.7 Hz, 3', 5'-H), 7.20 (d, 2H, 3J=8.7 Hz, 2',
US 9,718,799 B2 
39 
6'-H), 7.89 ppm (s, lH, 5-H); 13C NMR (100 MHz, CDCl3) 
Ii 8.33, 19.54, 20.95, 28.47, 32.20, 41.33, 50.63, 55.29, 
109.19, 113.70, 113.91, 118.35, 119.84, 122.75, 124.08, 
125.16, 131.54, 151.26, 153.58, 159.11, 163.11, 163.96, 







: C, 75.33; H, 6.09. Found: C, 75.52; H, 
5.87. 
General Procedure for the Synthesis of Diels-Alder 
Adducts 23 and 24. 
40 
MS (CI): m/z 349.2 (MH+, 100). Anal. Calcd for C23H2205 : 
C, 73.00; H, 5.86. Found: C, 72.71; H, 5.98. 
3-(3,4-Dimethoxyphenyl)-7 a-hydroxy-8,9, 10, 11, 11 a, 
12-hexahydro-4H, 7 aH-pyrano[2,3-a ]xanthen-4-one
(24b) 
To a solution of 2 mmol of 18 in 10 mL of N,N­
dimethylformamide was added 2.2 mmol (1.1 eq) of 1-mor­
pholinocyclopentene or 1-morpholinocyclohexene. The 
mixture was heated at 154° C. for 4 h. The solvent was 
evaporated in vacuo, and residue was chromatographed 
using 1:50 methanol-dichloromethane to afford 23 or 24. 
Pale yellow solid (85% yield); mp 214-216° C.; IR (KBr) 
v
max 
2930, 1629, 1612, 1516, 1439, 1263, 1143, 1027 cm-1; 
1H NMR (400 MHz, DMSO-d
6
) Ii 1.40-2.62 (m, 9H, 8, 9,
10 10, ll-CH
2
, lla-CH), 2.70-3.60 (m, 2H, 12-CH
2
), 3.75 (s, 
6H, 3', 4'-0CH
3
), 6.84-6.99, 7.07-7.19 (2m, 4H, 6, 2', 5', 
6'-H), 7.81-7.87 (m, lH, 5-H), 8.42, 8.43 ppm (2s, lH, 2-H); 
13C NMR (125 MHz, DMSO-d
6
) Ii 22.22 (22.13), 23.25
(23.42), 25.35 (24.73), 29.54 (29.02), 36.76 (35.87), 37.94 
7-Hydroxy-3-( 4-methoxyphenyl)-2-methyl-8-[ (2-
oxocyclopentyl )methy l]-4 H-chromen-4-one (23 g)
15 (37.71), 55.96, 55.96, 98.54 (98.13), 109.39 (109.30), 
111.95 (111.62), 113.17, 116.10 (116.07), 117.56 (117.78), 
121.63 (121.66), 123.63 (123.63), 124.28, 124.90 (124.91), 
148.68, 149.03, 153.79, 154.63 (155.32), 157.27 (156.79), 
175.28 (175.26) ppm; MS (CI): m/z 409.2 (MW, 100).Anal. 
Pale yellow solid (58% yield); mp 210-211 ° C.; IR (KBr) 
v
m
ax 2960, 1735, 1631, 1580, 1512, 1436, 1291, 1244 cm-1; 
2° Calcd for C
24H2406: C, 70.58; H, 5.92. Found: C, 70.31; H,
6.21. 
1H NMR (400 MHz, CDCl
3
) Ii 1.62-2.25 (m, 4H, 4",
5"-CH
2
), 2.33 (s, 3H, 2-CH
3
), 2.38-2.63 (m, 2H, 3"-CH
2
), 
3.01-3.17 (m, 2H, 8-CH
2
), 3.37-3.74 (m, lH, 1"-H), 3.84 (s, 
3H, 4'-0CH
3
), 6.91-7.00 (m, 3H, 6, 3', 5'-H), 7.21 (d, 2H, 25 
3J=8.6 Hz, 2', 6'-H), 7.99 ppm (d, lH, 3J=8.7 Hz, 5-H); 13C
NMR (125 MHz, DMSO-d
6
) Ii 19.15, 20.05, 22.40, 28.91, 
37.40, 48.03, 55.04, 113.25, 113.43, 113.69, 115.56, 121.25, 
124.27, 125.31, 131.67, 155.07, 158.46, 159.94, 162.29, 







: C, 73.00; H, 5.86. Found: C, 73.26; H, 
5.62. 
3-(1,3-Benzodioxol-5-yl)-7 a-hydroxy-8,9, 10, 11, 11 a, 
12-hexahydro-4H, 7 aH-pyrano[2,3-a ]xanthen-4-one
(24c) 
Pale yellow solid (76% yield); mp 197-197° C.; IR (KBr) 
v
max 
2937, 1630, 1587, 1435, 1251, 1027 cm-1; 1H NMR
(400 MHz, DMSO-d
6
) ll 1.23-2.62 (m, 9H, 8, 9, 10, ll-CH
2
, 
lla-CH), 2.70-3.60 (m, 2H, 12-CH
2
), 6.05 (s, 2H, OCH
2
0), 
6.88-7.18 (2m, 4H, 6, 2', 5', 6'-H), 7.81-7.99 (m, lH, 5-H), 
8.41, 8.45 ppm (2s, lH, 2-H); 13C NMR (125 MHz, DMSO­
d
6
) Ii 22.24 (22.14), 23.24 (23.42), 25.35 (24.72), 29.53 
(29.02), 36.76 (35.88), 37.95 (37.70), 98.56 (98.15), 101.45, 3-(3 ,4-Dimethoxyphenyl )-7-hydroxy-2-methy 1-8-
[ (2-oxocyclopenty I )methy l]-4 H-chromen-4-one 
(23h) 
35 108.51, 109.83 (109.86), 111.65, 116.13 (116.10), 117.49 
(117.72), 122.81 (122.84), 123.58 (123.63), 124.29, 126.11 
(126.13), 147.34, 147.41, 153.86 (153.64), 154.64 (155.33), 
Pale yellow solid (53% yield); mp 88-90° C.; IR (KBr) 157.32 (156.86), 175.16 (175.15) ppm; MS (CI): m/z 393.2 
v
m






: C, 70.40; H, 5.14.
(400 MHz, DMSO-d
6
) Ii 1.51-2.07 (m, 4H, 4", 5"-CH2), 40 Found: C, 70.14; H, 4.85. 
2.27 (s, 3H, 2-CH
3
), 2.66-3.16 (m, 4H, 8, 3"-CH
2
), 3.36-
3.60 (m, lH, 1 "-H), 3.74, 3.79 (2s, 6H, 3', 4'-0CH3), 
6.74-6.88 (m, 2H, 2', 6'-H), 6.93-7.03 (m, 2H, 6, 5'-H), 7.76 
7 a-Hydroxy-3-( 4-methoxyphenyl)-2-methyl-8,9, 10, 
11, 11 a, l 2-hexahydro-4H, 7 aH-pyrano[2,3-a ]xanthen-
4-one (24g)
Pale yellow solid (69% yield); mp 212-213° C.; IR (KBr) 
v
max 
2924, 1632, 1608, 1514, 1435, 1251, 1177 cm-1; 1H
NMR (400 MHz, CDCl
3
) Ii 1.57-2.17 (m, 9H, 8, 9, 10, 
ll-CH
2
, lla-CH), 2.33 (s, 3H, 2-CH
3
), 2.54-3.27 (m, 2H,
(d, lH, 3J=8.7 Hz, 5-H), 10.64 ppm (s, lH, 7-0H); 13C NMR
(125 MHz, DMSO-d
6
) Ii 19.63, 20.47, 29.33, 37.83, 48.43, 45 
55.93, 55.97, 111.89, 113.68, 114.12, 114.80, 116.05, 
122.01, 123.24, 124.70, 126.17, 148.54, 148.68, 155.50, 
160.34, 162.85, 175.75, 219.65 ppm; MS (CI): m/z 409.2 
(MH+, 100). Anal. Calcd for C
24H2406: C, 70.58; H, 5.92. 
Found: C, 70.28; H, 6.18. 50 12-CH
2
), 3.85 (s, 3H, 4'-0CH3), 6.70-6.81 (m, lH, 6-H), 
6.97 (d, 2H, 3J=8.5 Hz, 3', 5'-H), 7.21 (d, 2H, 3J=8.5 Hz, 2', 
6'-H), 7.87-7.97 ppm (m, lH, 5-H); 13C NMR (400 MHz,
CDCl
3
) ll 19.43 (19.44), 22.12 (21.97), 23.09 (23.34), 25.51 




55 97.93 (97.76), 110.68 (108.50), 113.85, 115.24 (115.21), 
116.93 (117.14), 122.74 (122.77), 124.61 (124.70), 125.50 
(125.51), 131.61, 154.48 (155.18), 155.81 (156.39), 159.02, 
162.51 (162.51), 177.10 (177.07) ppm; MS (CI): m/z 393.2 
(MH+, 100). Anal. Calcd for C
24H2405 : C, 73.45; H, 6.16. 
Pale yellow solid (91 % yield); mp 222-223° C.; IR (KBr) 
v
m
ax 2987, 1613, 1513, 1439, 1251, 1030 cm-1; 1H NMR
(400 MHz, CDCl
3
) Ii 1.30-2.18 (m, 9H, 8, 9, 10, ll-CH
2
, 
lla-CH), 2.35-3.26 (m, 2H, 12-CH
2
), 3.85 (s, 3H, 4'-0CH
3
), 
6.81-6.89 (m, lH, 6-H), 6.98 (d, 2H, 3J=8.6 Hz, 3', 5'-H), 
7.51 (d, 2H, 3J=8.6 Hz, 2', 6'-H), 7.96 (s, lH, 2-H), 8.02-8.09 
ppm (m, lH, 5-H); 13C NMR (125 MHz, DMSO-d
6
) ll 21.82
(21.73), 22.82 (23.00), 24.93 (24.30), 29.11 (28.59), 36.33 
(35.45), 37.51 (37.28), 55.13, 98.10 (97.70), 111.20 
(108.97), 113.58, 115.63 (115.65), 117.11 (117.33), 123.13 65 
(123.18), 123.84, 124.16, 130.06 (130.08), 153.15, 154.26 
(154.95), 156.84 (156.37), 158.96, 174.88 (174.86) ppm; 
60 Found: C, 73.18; H, 6.42. 
3-(3,4-Dimethoxyphenyl)-7a-hydroxy-2-methyl-8,9, 
10,11,l la,12-hexahydro-4H, 7aH-pyrano[2,3-a ]xan­
then-4-one (24h) 
Pale yellow solid (51% yield); mp 193-194; IR (KBr) 
v
max 
2938, 1631, 1610, 1577, 1514, 1437, 1264, 1028 cm-1; 
US 9,718,799 B2 
41 
1H NMR (400 MHz, CDC13) Ii 1.30-2.16 (m, 9H, 8, 9, 10, 
ll-CH
2
, lla-CH), 2.34 (s, 3H, 2-CH3), 2.53-3.28 (m, 2H,
12-CH2), 3.88, 3.92 (2s, 6H, 3', 4'-0CH3), 6.62-6.99 (m, lH,
6-H), 6.78-6.86, 6.90-6.96 (2m, 3H, 2', 5', 6'-H), 7.84-7.92
ppm (m, lH, 5-H); 13C NMR (125 MHz, DMSO-d
6) ll 19.19 5 
(19.21), 21.76 (21.69), 22.80 (22.99), 24.96 (24.32), 29.10
(28.59), 36.36 (35.46), 37.57 (37.31), 55.47, 55.50, 97.97
(97.58), 110.87 (108.64), 111.41, 114.31, 115.20 (115.17),
116.05 (116.27), 122.02 (122.08), 122.80, 123.64, 125.65
(125.67), 148.13, 148.22, 153.81 (154.50), 156.65 (156.16), lO 
162.53, 175.20 (175.17) ppm; MS (CI): m/z 423.2 (MW,
100). Anal. Calcd for C25H2606 : C, 71.07; H, 6.20. Found: 












wherein Ar is diazinyl, pyrimidinyl, oxazolyl or imidazolyl; 
n is an integer from 1 to 5; each Xis independently a halide, 
or alkoxy, or more than one X on Ar together form a cyclic 
Only the preferred embodiment of the present invention 15 ether structure; and wherein the compound is substituted on 
and examples of its versatility are shown and described in the C-2 position with H, alkyl, cycloalkyl or alkoxy, sub-
the present disclosure. It is to be understood that the present stituted on the C-5, C-6, C-7, and C-8 positions indepen-
invention is capable of use in various other combinations dently with H, hydroxy (OH), alkyl, cycloalkyl, alkoxy, 
and environments and is capable of changes or modifications 20 acetyl, ester, acetoxy, or the substituents on either C-6 and
within the scope of the inventive concept as expressed C-7 or the substituents on C-7 and C-8 together form a 
herein. Thus, for example, those skilled in the art will 
recognize, or be able to ascertain, using no more than routine 
substituted or unsubstituted, saturated or unsaturated, cyclic 
or polycyclic ring structure which includes at least one 
experimentation, numerous equivalents to the specific sub- 25 
chalcogen. 
stances, procedures and arrangements described herein. 
Such equivalents are considered to be within the scope of 
this invention, and are covered by the following claims. 
What is claimed is: 
1. A compound having formula (I) or pharmaceutically











4. The compound of claim 1 wherein the C-7 substituent
is hydroxy (OH), alkyl, cycloalkyl, alkoxy, acetyl, ester, or 
acetoxy, and the C-8 substituent is alkoxy, acetyl, ester, 
30 acetoxy, or CH20Y
1
. 
5. The compound of claim 1, wherein the C-2 substituent
is hydrogen H or methyl; Ar includes one or two X groups 
on the aryl that can be halogens or alkoxy groups or together 
35 form a ring structure; the C-5 substituent is H, hydroxy or
alkoxy; the C-6 substitutent is hydrogen H; the C-7 sub­
stituent is hydroxy or alkoxy; or either C-6 and C-7 together 
or C-7 and C-8 together form a ring structure including an 
40 
oxygen.
6. A pharmaceutically acceptable composition comprising
a compound of claim 1 or a pharmaceutically acceptable salt 
thereof and a pharmaceutically acceptable additive. 
7. A method of treating prostate cancer, the method
45 comprising administering to a patient in need of such
treatment an effective amount of a compound of claim 1 or 
pharmaceutically acceptable salt thereof or a pharmaceutical 
composition thereof. 
wherein Ar is phenyl; n is an integer from 1 to 5; each X is 
independently a halide, or alkoxy, or more than one X on Ar 
together form a cyclic ether structure; and wherein the 
compound is substituted on the C-2 position with H, alkyl, 
cycloalkyl or alkoxy, substituted on the C-5, C-6, and C-7 
positions independently with H, hydroxy (OH), alkyl, 50 
cycloalkyl, alkoxy, acetyl, ester, acetoxy, substituted on the 
C-8 position with hydroxy (OH), cycloalkyl, alkoxy, acetyl,
ester, acetoxy, CH
2
0Y1 where Y1 is hydrogen, alkyl, acetyl
8. A pharmaceutically acceptable composition comprising
a compound of claim 3 or a pharmaceutically acceptable salt
thereof and a pharmaceutically acceptable additive.
9. The compound of claim 1, wherein the C-7 substituent
is hydroxy (OH), alkoxy, acetyl, or acetoxy, and the C-8 
55 substituent is CH20Y
1
. 
or the substituents on either C-6 and C-7 or the substituents
on C-7 and C-8 together form a substituted or unsubstituted,
saturated or unsaturated, cyclic or polycyclic ring structure
which includes at least one chalcogen, wherein the alkyl,
cycloalkyl, and alkoxy substituents can be substituted with
one or more of a hydroxy, ester, acetoxy, alkoxy, or carbonyl.
2. The compound of claim 1, wherein the substituents on
C-6 and C-7 or the substituents on C-7 and C-8 together
form a substituted or unsubstituted, saturated or unsaturated,
cyclic or polycyclic ring structure which includes at least
one oxygen.
3. A compound having formula (I) or a pharmaceutically
acceptable salt thereof: 
60 
10. The compound of claim 1, wherein the substituents on 
C-6 and C-7 together form a substituted or unsubstituted, 
saturated or unsaturated, cyclic or polycyclic ring structure 
which includes at least one oxygen. 
11. The compound of claim 1, wherein the substituents on 
C-7 and C-8 together form a substituted or unsubstituted, 
saturated or unsaturated, cyclic or polycyclic ring structure 
65 
which includes at least one oxygen.
12. The compound of claim 1, having one of the following
formula or a pharmaceutically acceptable salt thereof: 
43 












wherein each of X2 and X3 is independently a halide, or 
alkoxy, or X2 and X3 together form a cyclic ether structure. 
13. A compound having one of the following formula or

















wherein each of X2 and X3 is independently a halide, or 
alkoxy, or X2 and X3 together form a cyclic ether structure. 
* * * * *
